var title_f36_12_37056="Ultrasound normal radial nerve";
var content_f36_12_37056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1104px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/58279/US_norm_radial_nerve_conv.mp4?title=Ultrasound+normal+radial+nerve\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Ultrasound normal radial nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an axial image of the normal radial nerve at the level of the antecubital fossa. In this image, the radial nerve is deep to the brachioradialis (B) and appears as two bright rounded fascicles. The fascicle to the right becomes the superficial radial sensory branch (S), and the fascicle to the left, the deep motor branch (M) of the radial nerve. They can be seen to separate in this real-time image as the probe is moved distally. To the lower left the bone shadow is that of the proximal radius and just above it, the supinator.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37056=[""].join("\n");
var outline_f36_12_37056=null;
var title_f36_12_37057="Mumps orchitis";
var content_f36_12_37057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mumps orchitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 279px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Epididymo-orchitis is the most common complication of mumps infection in the adult male. It is frequently characterized by the abrupt onset of fever from 39 to 41&ordm;C and severe testicular pain, accompanied by swelling and erythema of the scrotum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lawrence B Stack, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37057=[""].join("\n");
var outline_f36_12_37057=null;
var title_f36_12_37058="Burch medial displace bladder";
var content_f36_12_37058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medial displacement of the bladder for suture placement during Burch procedure (retropubic colposuspension)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Robinson, D, Norton, PA. Diagnosis and Management of Urinary Incontinence. In: Gynecologic Surgery. Mann, WJ, Stovall, TG (Eds), Churchill Livingstone, New York 1996. p.713.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37058=[""].join("\n");
var outline_f36_12_37058=null;
var title_f36_12_37059="CPAM type 1 gross pathology";
var content_f36_12_37059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gross pathology of a type 1 congenital pulmonary airway malformation (CPAM)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross pathology specimen from the lung of the patient with congenital pulmonary airway malformation (CPAM) type 1. A single, large, thin-walled, septate cyst is demonstrated.",
"    <div class=\"footnotes\">",
"     * CPAM was previously known as congenital cystic adenomatoid malformation (CCAM).",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher M Oermann, MD, and Claire Langston, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37059=[""].join("\n");
var outline_f36_12_37059=null;
var title_f36_12_37060="Ruxolitinib: Patient drug information";
var content_f36_12_37060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ruxolitinib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=see_link\">",
"     see \"Ruxolitinib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13376660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Jakafi&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14732981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Jakavi&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13385821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13385838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3567682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat myelofibrosis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13385804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3567663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ruxolitinib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13385806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for any infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13385840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bruising.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13385807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13385839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3567683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the tablet. Mix each tablet with 40 mL of water. Stir for 10 minutes. Give within 6 hours of mixing. Flush the feeding tube with water before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13385805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696552",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Never make up a missed dose. Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13385841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13385808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17097 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37060=[""].join("\n");
var outline_f36_12_37060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376660\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14732981\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385821\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385838\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385804\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385806\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385840\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385807\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385839\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385805\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385841\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13385808\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/35/29239?source=related_link\">",
"      Ruxolitinib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_12_37061="Chronic irritant contact dermatitis 2";
var content_f36_12_37061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Chronic irritant contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema, fissuring, and scaling resulting from repeated exposure to irritants.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37061=[""].join("\n");
var outline_f36_12_37061=null;
var title_f36_12_37062="L1 lymphoblasts";
var content_f36_12_37062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphoblasts in acute lymphoblastic leukemia FAB L1 morphologic phenotype",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with acute lymphoblastic leukemia, showing French American British (FAB) L1 morphology. The blast cells have a high nuclear to cytoplasmic ratio; many cells have only a thin rim of deep blue cytoplasm. The nucleus may have several distinct and/or indistinct nucleoli. (Wright-Giemsa).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37062=[""].join("\n");
var outline_f36_12_37062=null;
var title_f36_12_37063="Heart failure and hemodialysis arteriovenous fistulae";
var content_f36_12_37063=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Heart failure and hemodialysis arteriovenous fistulae",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37063/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37063/contributors\">",
"     Gerald A Beathard, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37063/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37063/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37063/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37063/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/12/37063/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease is a well-recognized and important source of mortality in patients with chronic kidney disease, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Data collected by United States Renal Data System indicated that the risk of death in a dialysis patient with heart failure is 0.33, 0.46, and 0.57 at 12, 24, and 36 months after initiating dialysis respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/4\">",
"     4",
"    </a>",
"    ]. Although the presence of an arteriovenous fistula (AVF) has an adverse effect on cardiac function, the exact role of the vascular access in contributing to this morbidity is unclear.",
"   </p>",
"   <p>",
"    The effect of AV fistulae on cardiovascular dynamics and the management of AV fistulae causing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exacerbating heart failure are presented in this topic review. An overview of myocardial dysfunction in the patient with end-stage renal disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECTS OF AV FISTULA CREATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several cardiovascular effects of AVF creation. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased cardiac output",
"     </li>",
"     <li>",
"      Decreased systemic peripheral resistance",
"     </li>",
"     <li>",
"      Increased sympathetic activity with increased contractility, heart rate and stroke volume",
"     </li>",
"     <li>",
"      Increased blood volume with increased atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and left ventricular end-diastolic volume",
"     </li>",
"     <li>",
"      Increased pulmonary flow and pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2307229\">",
"    <span class=\"h2\">",
"     Increased cardiac output and high output cardiac failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association of an AVF with heart failure was reported within a few years of the first report of the creation of an AVF for hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Although heart failure has been attributed to changes in cardiac output, specifically high output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], most experts believe that symptomatic heart failure is not commonly associated with an AVF, and generally occurs only in patients with underlying cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few prospective studies have examined the immediate impact on the heart of the opening of an AVF. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 30 patients, the cardiac output increased from 6.5 to7.6",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      (17 percent) two weeks after successful AVF surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective short-term echocardiographic study, 16 patients with CKD underwent echocardiographic studies before and after AVF creation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/12\">",
"       12",
"      </a>",
"      ]. There were significant elevations in left ventricular end-diastolic diameter (4 percent) and a significant increase in cardiac output (CO) after AVF creation. At 3 days, the CO went from a mean of 4.74 + 0.22 to 5.22 + 0.20",
"      <span class=\"nowrap\">",
"       L/min,",
"      </span>",
"      an increase of 10 percent, and by 14 days, the mean CO was 5.41 + 0.17, representing an additional increase of 4 percent.",
"      <br/>",
"      <br/>",
"      Additional observations from this study included an 18 percent increase in the ratio of the peak velocity of early diastolic to atrial filling and a 12 percent shortened deceleration time, suggesting a restrictive pattern of left ventricular diastolic dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these changes are not sufficient to cause heart failure in the patient with good left ventricular function, they may be problematic for the patient with reduced ventricular function.",
"   </p>",
"   <p>",
"    The mechanism by which an AVF affects CO is not well understood and the relationship between AVF blood flow and systemic blood flow does not appear to be linear. One study showed that the mean CO remains largely unchanged between blood flows up to approximately 2",
"    <span class=\"nowrap\">",
"     L/",
"    </span>",
"    min but high cardiac output failure results when the AVF blood flow significantly exceeds 2.0",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/13\">",
"     13",
"    </a>",
"    ]. The presence of myocardial functional reserve and myocardial adaptation may protect against high-output cardiac failure.",
"   </p>",
"   <p>",
"    In addition, the effect of blood volume on AVF blood flow and CO is not known. In one study that examined the effect of blood volume changes on AVF blood flow and CO during hemodialysis, the AVF access blood flow did not change with significant reductions in blood volume, but the cardiac output decreased, thus increasing the ratio of AVF blood flow to cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/8\">",
"     8",
"    </a>",
"    ]. This change may be mediated by reflex vasoconstriction of the systemic circulation.",
"   </p>",
"   <p>",
"    As noted above, high-output cardiac failure, defined as symptoms of cardiac failure in the presence of an above normal cardiac index, is a rare complication of high-flow AVFs. Multiple case reports have document that the long-term effects of a high-flow AVF can adversely affect cardiac function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/6,7,13-17\">",
"     6,7,13-17",
"    </a>",
"    ], although as noted above, cardiac decompensation due to an AVF is likely to occur only in patients with underlying cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The calculated ratio of QA to CO (cardio-pulmonary recirculation or CPR) may be used to evaluate the relationship between the AV access and heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/8\">",
"     8",
"    </a>",
"    ]. In one a study of stable long-term hemodialysis patients, the average AV access blood flow was 1.6",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    and the average CO was 7.2",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    resulting in an average CPR of 22 percent. The authors of this study suggested that a CPR higher than 0.3 should be considered a risk factor for high-output cardiac failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One case series reported on 17 patients with high output heart failure related to a dialysis vascular access, all which were upper arm AVFs with a brachial artery anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/19\">",
"     19",
"    </a>",
"    ]. The mean CO was 8 + 3.1",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    (range 5.1 to 15.1), the AVF blood flow was 3135 + 692",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (range 1850 &ndash; 4000) and the mean CPR was 0.377 (95% CI 0.26&ndash;0.61). Patients were treated using a technique referred to as distalization of the inflow which consists of ligation of the brachial anastomosis and reconstruction of the fistula by using an expanded polytetrafluoroethylene vascular graft in a bypass from the radial artery. The mean access inflow rate decreased after the inflow reduction procedure, from 3135 to 1025",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    The mean cardiac output decreased from 8 to 5.6",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    and the CPR decreased to 0.187, with resolution of symptoms. Thirteen of the 17 accesses (77 percent) subjected to the inflow reduction procedure remained patent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2307387\">",
"    <span class=\"h2\">",
"     Decreased peripheral vascular resistance and effects on cardiac mechanics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac output (CO) increases immediately on opening an AVF. This increase is mediated by the reduction in total peripheral vascular resistance, a fall in both central and peripheral blood pressure, an increase in sympathetic nervous system activity (increasing contractility), and an increase in stroke volume and heart rate in order to maintain blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/11,13,20\">",
"     11,13,20",
"    </a>",
"    ]. The decrease in total peripheral vascular resistance is due to changes in the vessels associated with the AV access (called access resistance [AR]) and changes in the systemic vessels (systemic vascular resistance [SVR-AR]).",
"   </p>",
"   <p>",
"    Experimental and clinical data indicate that the vascular endothelium responds to the short-term increases in blood flow and shear stress by releasing nitric oxide and other endothelium-dependent relaxing factors that dilate the artery and try to reduce shear stress towards normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/11,21\">",
"     11,21",
"    </a>",
"    ]. One study showed that mean shear stress increased by 475 percent and brachial artery diameter by 15 percent within one day following placement of a radio-cephalic AVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although chronic kidney disease (CKD) is associated with elevations in both plasma atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) concentrations even among patients without an AVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/23-26\">",
"     23-26",
"    </a>",
"    ], both peptides increase further after opening of an AVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/12,27\">",
"     12,27",
"    </a>",
"    ]. As an example, in one study pf CKD patients, ANP levels increased by 84 percent two weeks after AVF creation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/27\">",
"     27",
"    </a>",
"    ]. The increase in ANP was associated with an increase in contractility, stroke volume, and CO, and with a drop in the systemic vascular resistance. Renin activity decreased and aldosterone levels remained unchanged.",
"   </p>",
"   <p>",
"    In another study, ANP and BNP increased by 35 and 41 percent, respectively, by day 10 post-AVF creation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/12\">",
"     12",
"    </a>",
"    ]. The increase in ANP was attributed to atrial volume expansion and atrial stretching. The increase in BNP was attributed to the left ventricular dysfunction. This proposed mechanism suggests that the increase in BNP re���ects the degree of left ventricular pressure overload and that of ANP re���ects the degree of volume overload resulting from the opening of the AVF.",
"   </p>",
"   <p>",
"    Studies have suggested that the increase in AVF-induced increase in CO is due primarily to the change in AR rather that changes in SVR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2307810\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;End-stage renal disease (ESRD) itself and AV access-mediated increases in CO both contribute to the development of pulmonary hypertension (PHT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Support for the role of the AVF is derived from studies that have shown a return of elevated pulmonary artery pressure (PAP) and CO towards normal following the ligation of a functioning AVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/32\">",
"     32",
"    </a>",
"    ]. Additionally, a significant decrease in both the elevated PAP and CO has been reported following compression of the AVF for a one minute interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for the role of ESRD itself was provided by two studies in which patients with a patent AVF were evaluated before and after a successful renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Both of these studies showed that the PAP decreased significantly after the resolution of kidney failure by the transplant.",
"   </p>",
"   <p>",
"    The mechanism by which ESRD contributes to PHT is not known. Local vascular tone and function are regulated by the balance between vasodilators, such as nitric oxide (NO), and vasoconstrictors, such as endothelin-1 (ET-1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Pulmonary endothelial cells normally increase the synthesis of NO in response to increases in pulmonary blood flow and pressure in an attempt to restore normal vascular tone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/37\">",
"     37",
"    </a>",
"    ]. Endothelial dysfunction related to these mediators has been described in patients with primary PHT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], and a pathogenic role for this defect has been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/40\">",
"     40",
"    </a>",
"    ]. A defect has also been described in the peripheral circulation of patients with ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to investigate the role of endothelial dysfunction in AVF-associated PHT, one study compared plasma ET-1 concentrations among hemodialysis patients with and without PHT, and among healthy subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/43\">",
"     43",
"    </a>",
"    ]. Plasma concentrations of ET-1 in the hemodialysis patients (combined groups) were significantly higher than those in normal subjects, but did not differ significantly between hemodialysis patients with and without PHT. Plasma concentrations of ET-1 were not changed by the dialysis procedure. Pre-dialysis plasma concentrations of NO metabolites in the in the two hemodialysis groups were similar to those in normal subjects. Following dialysis, plasma NO levels of both subgroups of hemodialysis patients increased significantly; however, the increase was greater in hemodialysis patients without PHT.",
"   </p>",
"   <p>",
"    The authors of this study proposed that a functional defect in the endothelium causes PTH in hemodialysis patients. This defect manifests as reduced NO production and augments the resistance of the pulmonary vascular bed and reduces the capacity of the pulmonary circulation to maintain the AV access-mediated elevated CO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A structural defect may also contribute to PHT. However, although an increased stiffness of the pulmonary capillaries due to pulmonary vascular calcification which has been shown to occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/12,44\">",
"     12,44",
"    </a>",
"    ], clinical studies have not found evidence of a structural defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that recurrent pulmonary emboli resulting from repeated thrombectomies might contribute to PHT among hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/32,45\">",
"     32,45",
"    </a>",
"    ]. One study compared the prevalence of PHT among hemodialysis patients with AV accesses who had previously undergone thrombectomy (n = 88) versus those who had not (n = 117) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/46\">",
"     46",
"    </a>",
"    ]. There was no difference between groups in the prevalence of PHT (52 and 42 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DECISIONS CONCERNING ACCESS PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart disease is a major risk factor for early death in the dialysis population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. In view of the adverse effects of an arteriovenous access on cardiac function, the possible contribution of AV access creation to increased mortality must be considered.",
"   </p>",
"   <p>",
"    Thus, the patient's cardiovascular status should influence decisions concerning dialysis access and even dialysis modality for the patient with end-stage renal disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Right heart failure may be exacerbated by the advent of pulmonary hypertension that accompanies the placement of an AVF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Failing left ventricular function may be aggravated by the increased demands of the blood flow of an AVF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/7,14\">",
"       7,14",
"      </a>",
"      ]. On the other hand, there might be some potential for after load benefit from the reduced resistance presented by the shunt.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with severe heart failure, New York Heart Association class IV, due to intrinsic heart disease are at considerable risk for worsening cardiac function with creation of an AVF. This risk is greater for an upper arm fistula than with one located in the forearm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. In a study of 96 patients with fistulas, for example, significantly higher blood flow rates were seen with those in the upper arm (1.58",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    versus the forearm (0.948",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/13\">",
"     13",
"    </a>",
"    ]. In this group, 10 cases of high-output cardiac failure were recognized. Seven of these had an upper arm fistula, although this access location was used in less than one-third of patients.",
"   </p>",
"   <p>",
"    There does not appear to be any difference between the risks of a fistula versus a graft; the risk relates to the blood flow achieved by the shunt and not its structural character [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of these issues, peritoneal dialysis rather than hemodialysis may be preferable in some patients with heart failure. In addition, some clinicians advocate the use of a tunneled dialysis catheter for long-term dialysis in the patient with severe heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/50\">",
"     50",
"    </a>",
"    ]. This may be the most reasonable choice, providing the patient is not a candidate for peritoneal dialysis.",
"   </p>",
"   <p>",
"    Unfortunately, there is an increased risk of adverse cardiovascular outcomes with tunneled catheters that derive from their frequent association with bacteremia and septicemia. In the WAVE 2 study, for example, a randomly selected prospective cohort of incident dialysis patients was studied to determine if there was an association between bacteremia or sepsis episodes and subsequent cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/51\">",
"     51",
"    </a>",
"    ]. Infectious problems were significantly associated with subsequent death, myocardial infarction, heart failure, peripheral vascular disease, and stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In making a decision about hemodialysis and placement of an AVF in a new patient with end-stage renal disease and heart failure, we consider the severity of heart failure as determined by the New York Heart Association (NYHA) Classification:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patient with category III or IV heart failure, we suggest the use of peritoneal dialysis rather than hemodialysis.",
"     </li>",
"     <li>",
"      If peritoneal dialysis is not possible in the patient with category III heart failure, creation of a forearm AVF for hemodialysis is preferred.",
"     </li>",
"     <li>",
"      If peritoneal dialysis is not possible in the patient with category IV heart failure, hemodialysis with a tunneled catheter would be acceptable as the only remaining alternative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, others would try to place an AVF in the patient who is not chronically hypotensive if vessels appear to be adequate and their life expectancy is sufficient to justify placement of an AVF. If this is done, the patient needs to be closely monitored for developing evidence of high-output failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROSPECTIVE MONITORING AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective monitoring for the development of high-output heart failure in the dialysis patient with an AV shunt type of access has been recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/7\">",
"     7",
"    </a>",
"    ]. We suggest ongoing",
"    <span class=\"nowrap\">",
"     monitoring/surveillance",
"    </span>",
"    of patients at increased risk, which is defined as patients of advanced age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with a history of heart disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an upper arm access.",
"   </p>",
"   <p>",
"    We agree with the",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    Practice Guidelines which recommend that access monitoring (physical examination) be done weekly and that surveillance be performed on a regular (monthly) basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With physical examination, the presence of a large distended fistula with very strong pulse augmentation and thrill is suspicious for high blood flow.",
"     </li>",
"     <li>",
"      For surveillance, we prefer to measure access blood flow. Patients with a blood flow rate in excess of 2",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      should be considered at increased risk for the development of heart failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another useful indicator for increased risk of heart failure due to the AV access is the ratio of flow between the access (QA) and the cardiac output (CO). A QA:CO ratio greater than 0.3 indicates a significant risk of developing high-output cardiac failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We measure the QA:CO ratio in the patient with heart failure and high flow access (apparent on physical examination or with actual flow measurements) or with progressive heart failure despite the usual approaches to medical management. If the ratio exceeds 0.3, then the patient's management should address mitigating excessive access flow.",
"   </p>",
"   <p>",
"    However, in the patient with intractable clinical heart failure, an adverse effect from the access should be evaluated as a possible contributing factor even if the QA:CO ratio is less than 0.3. In this setting, consideration should be given to",
"    <span class=\"nowrap\">",
"     altering/removing",
"    </span>",
"    the adverse cardiovascular effects from the dialysis access.",
"   </p>",
"   <p>",
"    This condition is characterized by symptoms that are generally identical to those of heart failure. Since heart failure is common among dialysis patients, the ability to distinguish heart failure resulting from the AV access from that due to myocardial dysfunction alone can be difficult. The diagnosis of heart failure due to the AV access is essentially made if improvement is observed with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient with heart failure due in part to an AVF, management begins with basic fluid control, correction of anemia and pharmacologic management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If heart failure remains uncontrolled despite conservative therapy, we attempt to reduce the cardiac work load presented by the dialysis access.",
"   </p>",
"   <p>",
"    We suggest the following stepped approach in patients with high-output heart failure due to an AVF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an attempt to salvage the access, the first attempt should be directed at reducing access blood flow using a procedure such as distalization of the anastomosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If this is ineffective, then closing the arteriovenous shunt is necessary. Banding has been used, but unfortunately attempts at banding often lead to loss of the access.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rarely, the patient may have more than one functioning arteriovenous access. In this setting, one should be closed immediately.",
"   </p>",
"   <p>",
"    Although there are no reports of its use for this indication, good results have also been obtained with banding using the MILLER technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/54\">",
"     54",
"    </a>",
"    ]. This is a technique, advocated for use to treat steal syndrome, by which a very controlled banding procedure can be easily accomplished. A 4 mm in diameter angioplasty balloon is placed with the access adjacent to the arterial anastomosis, and the access is then banded over the inflated balloon. This leaves a 4 mm orifice for flow. The incidence of access loss due to thrombosis resulting from the decreased flow has been very low with this procedure.",
"   </p>",
"   <p>",
"    There is a report of a heart failure NYHA IV renal transplant patient with fatal evolution after surgical closure of a high-flow AV fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37063/abstract/55\">",
"     55",
"    </a>",
"    ]. This was attributed to the abrupt increase in peripheral resistance that resulted from the sudden loss of the low resistance shunt",
"   </p>",
"   <p>",
"    Patients unable to tolerate a hemodialysis fistula due to high output cardiac failure should be converted to peritoneal dialysis or hemodialyzed via a permanent indwelling cuffed catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Creation of an arteriovenous fistula (AVF) has significant effects on both systolic and diastolic function. It is associated with increased blood flow, pulmonary hypertension, and cardiac output. Although usually clinically insignificant, the increased cardiac output and blood flow may be so great at times that they result in overt cardiac failure. This is particularly true if the patient has underlying heart disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the access has flows greater than 2000",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effects of AV fistula creation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient's cardiovascular status should influence decisions about type of dialysis modality and dialysis access. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that",
"      <span class=\"nowrap\">",
"       monitoring/surveillance",
"      </span>",
"      be performed in patients at increased risk defined as patients of advanced age",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those with a history of heart disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an upper arm access. We recommend that access monitoring (physical examination) be done weekly and that surveillance be performed on a regular (monthly) basis. If a clinical picture of heart failure is evident or emerges over time, the patient should also be evaluated by determining the ratio of flow between the access (QA) and the cardiac output (CO). A QA:CO ratio greater than 0.3 is associated with an increased risk for high-output cardiac failure. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prospective monitoring and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary indication for treatment is intractable heart failure. If basic fluid control and pharmacological management is not effective, then some approach to the reduction in cardiac work load presented by the access should be taken. In an attempt to preserve the dialysis access, the first approach to treatment of this complication should be a flow reduction procedure. If this is not successful, then access closure should be considered. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/1\">",
"      Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/2\">",
"      Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol 2004; 44:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/3\">",
"      Shlipak MG, Stehman-Breen C, Vittinghoff E, et al. Creatinine levels and cardiovascular events in women with heart disease: do small changes matter? Am J Kidney Dis 2004; 43:37.",
"     </a>",
"    </li>",
"    <li>",
"     US Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda; MD 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/5\">",
"      Brescia MJ, Cimino JE, Appel K, Hurwich BJ. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. N Engl J Med 1966; 275:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/6\">",
"      Ahearn DJ, Maher JF. Heart failure as a complication of hemodialysis arteriovenous fistula. Ann Intern Med 1972; 77:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/7\">",
"      MacRae JM, Pandeya S, Humen DP, et al. Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. Am J Kidney Dis 2004; 43:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/8\">",
"      Pandeya S, Lindsay RM. The relationship between cardiac output and access flow during hemodialysis. ASAIO J 1999; 45:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/9\">",
"      Sandhu JS, Wander GS, Gupta ML, et al. Hemodynamic effects of arteriovenous fistula in end-stage renal failure. Ren Fail 2004; 26:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/10\">",
"      Lazarides MK, Staramos DN, Panagopoulos GN, et al. Indications for surgical treatment of angioaccess-induced arterial \"steal\". J Am Coll Surg 1998; 187:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/11\">",
"      Korsheed S, Eldehni MT, John SG, et al. Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function. Nephrol Dial Transplant 2011; 26:3296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/12\">",
"      Iwashima Y, Horio T, Takami Y, et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002; 40:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/13\">",
"      Basile C, Lomonte C, Vernaglione L, et al. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol Dial Transplant 2008; 23:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/14\">",
"      Bednarek-Skublewska A, J&oacute;��wiak L, Przywara S, et al. [Acute cardiac failure secondary to brachiocephalic arteriovenous fistula in patient on chronic haemodialysis]. Pol Arch Med Wewn 2004; 112:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/15\">",
"      Chapman F, Blackmur JP, Fotheringham J, et al. An uncommon cause of pleural effusions in a dialysis patient. Lancet 2012; 380:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/16\">",
"      Engelberts I, Tordoir JH, Boon ES, Schreij G. High-output cardiac failure due to excessive shunting in a hemodialysis access fistula: an easily overlooked diagnosis. Am J Nephrol 1995; 15:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/17\">",
"      Young PR Jr, Rohr MS, Marterre WF Jr. High-output cardiac failure secondary to a brachiocephalic arteriovenous hemodialysis fistula: two cases. Am Surg 1998; 64:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/18\">",
"      Wijnen E, Keuter XH, Planken NR, et al. The relation between vascular access flow and different types of vascular access with systemic hemodynamics in hemodialysis patients. Artif Organs 2005; 29:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/19\">",
"      Chemla ES, Morsy M, Anderson L, Whitemore A. Inflow reduction by distalization of anastomosis treats efficiently high-inflow high-cardiac output vascular access for hemodialysis. Semin Dial 2007; 20:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/20\">",
"      GUYTON AC, SAGAWA K. Compensations of cardiac output and other circulatory functions in areflex dogs with large A-V fistulas. Am J Physiol 1961; 200:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/21\">",
"      Mitchell GF, Parise H, Vita JA, et al. Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. Hypertension 2004; 44:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/22\">",
"      Dammers R, Tordoir JH, Welten RJ, et al. The effect of chronic flow changes on brachial artery diameter and shear stress in arteriovenous fistulas for hemodialysis. Int J Artif Organs 2002; 25:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/23\">",
"      Buckley MG, Sethi D, Markandu ND, et al. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci (Lond) 1992; 83:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/24\">",
"      Naruse M, Takeyama Y, Tanabe A, et al. Atrial and brain natriuretic peptides in cardiovascular diseases. Hypertension 1994; 23:I231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/25\">",
"      Nishikimi T, Futoo Y, Tamano K, et al. Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis 2001; 37:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/26\">",
"      McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 2003; 4 Suppl 4:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/27\">",
"      Ori Y, Korzets A, Katz M, et al. Haemodialysis arteriovenous access--a prospective haemodynamic evaluation. Nephrol Dial Transplant 1996; 11:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/28\">",
"      van der Mark WA, Boer P, Cramer MJ, Blankestijn PJ. Decreased access resistance in haemodialysis patients with upper arm arteriovenous fistulae. Nephrol Dial Transplant 2008; 23:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/29\">",
"      Yigla M, Abassi Z, Reisner SA, Nakhoul F. Pulmonary hypertension in hemodialysis patients: an unrecognized threat. Semin Dial 2006; 19:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/30\">",
"      Abassi Z, Nakhoul F, Khankin E, et al. Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens 2006; 15:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/31\">",
"      Nakhoul F, Yigla M, Gilman R, et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 2005; 20:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/32\">",
"      Dolmatch BL, Gray RJ, Horton KM. Will iatrogenic pulmonary embolization be our pulmonary embarrassment? Radiology 1994; 191:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/33\">",
"      Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003; 123:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/34\">",
"      Yigla M, Keidar Z, Safadi I, et al. Pulmonary calcification in hemodialysis patients: correlation with pulmonary artery pressure values. Kidney Int 2004; 66:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/35\">",
"      Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research \"Work in progress\". Circulation 2000; 102:2781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/36\">",
"      Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002; 45:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/37\">",
"      Stamler JS, Loh E, Roddy MA, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 89:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/38\">",
"      Chen YF, Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 2000; 320:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/39\">",
"      Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/40\">",
"      Wever R, Boer P, Hijmering M, et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999; 19:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/41\">",
"      Morris ST, Jardine AG. The vascular endothelium in chronic renal failure. J Nephrol 2000; 13:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/42\">",
"      Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 2001; 38:S74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/43\">",
"      Amin M, Fawzy A, Hamid MA, Elhendy A. Pulmonary hypertension in patients with chronic renal failure: role of parathyroid hormone and pulmonary artery calcifications. Chest 2003; 124:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/44\">",
"      Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003; 42:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/45\">",
"      Smits HF, Van Rijk PP, Van Isselt JW, et al. Pulmonary embolism after thrombolysis of hemodialysis grafts. J Am Soc Nephrol 1997; 8:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/46\">",
"      Harp RJ, Stavropoulos SW, Wasserstein AG, Clark TW. Pulmonary hypertension among end-stage renal failure patients following hemodialysis access thrombectomy. Cardiovasc Intervent Radiol 2005; 28:17.",
"     </a>",
"    </li>",
"    <li>",
"     Mauri, JM, Vela, E, Cleries, M. Development of a predictive model for early death in diabetic patients entering hemodialysis: a population based study. Acta Diabetol 2008 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/48\">",
"      Bradbury BD, Fissell RB, Albert JM, et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007; 2:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/49\">",
"      Keuter XH, Kooman JP, Habets J, et al. Effect of upper arm brachial basilic and prosthetic forearm arteriovenous fistula on left ventricular hypertrophy. J Vasc Access 2007; 8:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/50\">",
"      NKF-K/DOQI Clinical Practice Guidelines For Vascular Access. Clinical Practice Guideline 2: Selection and placement of hemodialysis access. Am J Kidney Dis 2008; 48(Suppl 1):S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/51\">",
"      Ishani A, Collins AJ, Herzog CA, Foley RN. Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney Int 2005; 68:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/52\">",
"      NKF-K/DOQI Clinical Practice Guidelines For Vascular Access. Clinical Practice Guideline 4: Detection of access dysfunction: monitoring, surveillance, and diagnostic testing. Am J Kidney Dis 2008; 48(Suppl 1):S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/53\">",
"      Sidawy AN, Spergel LM, Besarab A, et al. The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access. J Vasc Surg 2008; 48:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/54\">",
"      Goel N, Miller GA, Jotwani MC, et al. Minimally Invasive Limited Ligation Endoluminal-assisted Revision (MILLER) for treatment of dialysis access-associated steal syndrome. Kidney Int 2006; 70:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37063/abstract/55\">",
"      Pascual J, Martins J, Bouarich H, et al. Sudden death after arteriovenous fistula ligation in a renal transplant patient. Ann Vasc Surg 2008; 22:134.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1958 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-33503A3141-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37063=[""].join("\n");
var outline_f36_12_37063=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECTS OF AV FISTULA CREATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2307229\">",
"      Increased cardiac output and high output cardiac failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2307387\">",
"      Decreased peripheral vascular resistance and effects on cardiac mechanics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2307810\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DECISIONS CONCERNING ACCESS PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROSPECTIVE MONITORING AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_12_37064="Treatment of pressure ulcers";
var content_f36_12_37064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of pressure ulcers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37064/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37064/contributors\">",
"     Dan Berlowitz, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37064/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37064/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37064/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37064/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/12/37064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure ulcers are a significant problem in institutionalized elderly patients and critically ill patients, causing pain, decreasing quality of life, and leading to significant morbidity and prolonged hospital stays.",
"   </p>",
"   <p>",
"    Pressure ulcers are ischemic soft tissue injuries resulting from pressure, usually over bony prominences (eg, sacrum, calcaneus, ischium) (",
"    <a class=\"graphic graphic_figure graphicRef80206 \" href=\"mobipreview.htm?28/46/29415\">",
"     figure 1",
"    </a>",
"    ). Pressure ulcers can also result from poorly fitting casts or appliances. Soft tissues are more susceptible to injury than skin. Accordingly, the external appearance of a pressure ulcer may underestimate the extent of injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to treatment of pressure ulcers is discussed here. Other aspects of pressure ulcer evaluation and prevention are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1049?source=see_link\">",
"     \"Prevention of pressure ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34120?source=see_link\">",
"     \"Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of pressure ulcers begins with a comprehensive assessment of both the patient's general medical condition and the wound. Wounds should be evaluated for stage, size, sinus tracts, necrotic tissue, exudate, and the presence of granulation. Photographs of all wounds are helpful.",
"   </p>",
"   <p>",
"    A number of staging systems have been developed to describe the extent of pressure ulcers. The most commonly used system, proposed by the National Pressure Ulcer Advisory Panel (",
"    <a class=\"external\" href=\"file://www.npuap.org/\">",
"     www.npuap.org",
"    </a>",
"    ), is outlined below (",
"    <a class=\"graphic graphic_table graphicRef62903 \" href=\"mobipreview.htm?20/62/21483\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50125 \" href=\"mobipreview.htm?19/1/19480\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34120?source=see_link&amp;anchor=H4#H4\">",
"     \"Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1 - The skin is intact with non-blanchable redness in a localized area, usually over a bony prominence. Darkly pigmented skin may not have visible blanching; its color may differ from the surrounding area.",
"     </li>",
"     <li>",
"      Stage 2 - Partial thickness loss of dermis, which presents as a shallow open ulcer with a red-pink wound bed, without sloughing. Stage 2 ulcers may also present as an intact or ruptured serum-filled blister.",
"     </li>",
"     <li>",
"      Stage 3 - Full thickness tissue loss. Subcutaneous fat may be visible, but bone, tendon or muscles are not exposed. Sloughing may be present but does not obscure the depth of tissue loss. There may be undermining and tunneling.",
"     </li>",
"     <li>",
"      Stage 4 - Full thickness skin loss with exposed bone, tendon or muscle. Sloughing or eschar may be present on some parts of the wound bed. These ulcers often include undermining and tunneling.",
"     </li>",
"     <li>",
"      Unstageable - In addition, pressure ulcers are considered unstageable when there is full thickness tissue loss and the base of the ulcer is covered by slough (yellow, tan, gray, green, or brown)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eschar (tan, brown, or black) in the wound bed. Until enough slough",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eschar is removed to expose the base of the wound, the true depth, and therefore stage, cannot be determined.",
"     </li>",
"     <li>",
"      Deep tissue injury - Deep tissue injury is suspected when there is purple or maroon localized area of discolored intact skin or blood-filled blister due to damage of underlying tissue from pressure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shear. The area may be recognized by tissue that is painful, firm, mushy, boggy, warmer, or cooler as compared to adjacent tissue. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34120?source=see_link\">",
"       \"Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures, with a focus on positioning and support to minimize tissue pressure, should be provided for all patients, including those with pressure ulcers. Any ulcer development should underscore the need to review and intensify preventive measures that are already in place. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1049?source=see_link\">",
"     \"Prevention of pressure ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of pressure ulcers depends on the stage and severity of the ulcer (",
"    <a class=\"graphic graphic_table graphicRef62903 \" href=\"mobipreview.htm?20/62/21483\">",
"     table 1",
"    </a>",
"    ). The general approach to management of a patient with a pressure ulcer should include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduce or eliminate underlying contributing factors by providing pressure relief with proper positioning and support surfaces.",
"     </li>",
"     <li>",
"      Provide appropriate local wound care, which may include debridement for patients with necrotic tissue, based on the ulcer's characteristics.",
"     </li>",
"     <li>",
"      Consider adjunctive therapies, such as negative pressure wound therapy",
"     </li>",
"     <li>",
"      Monitor and document the patient's progress",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following parameters of care should be monitored daily and documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of the ulcer",
"     </li>",
"     <li>",
"      Status of the dressing, if present",
"     </li>",
"     <li>",
"      Status of the area surrounding the ulcer",
"     </li>",
"     <li>",
"      Presence of pain, and adequacy of pain control",
"     </li>",
"     <li>",
"      Presence of possible complications, such as infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Documentation may be facilitated by using one of the scales for healing ulcers (",
"    <a class=\"graphic graphic_table graphicRef63890 \" href=\"mobipreview.htm?31/13/31964\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Healing Scales'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Appropriate therapeutic goals should be set that consider discharge potential, quality of life, treatment preferences, and prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Healing Scales",
"    </span>",
"    &nbsp;&mdash;&nbsp;The healing process is best described by scales that capture changes in surface area, extent of necrotic tissue and exudate, and the presence of granulation tissue. A number of scales are available for use in monitoring and documentation of the healing of pressure ulcers, including the Pressure Sore Status Tool (PSST) (",
"    <a class=\"graphic graphic_table graphicRef72135 \" href=\"mobipreview.htm?38/43/39612\">",
"     table 3",
"    </a>",
"    ), the Sessing Scale, the Wound Healing Scale, and the Pressure Ulcer Scale for Healing (PUSH) tool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The PUSH tool, designed to be used in conjunction with the NPUAP Staging System is the most readily applied tool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/10\">",
"     10",
"    </a>",
"    ]. This scale has been validated, is easy to use, and has been shown to be helpful in pressure ulcer management. Given differences among available staging systems, the healing scale used should be explicitly described to facilitate effective communication among clinicians responsible for patients with a pressure ulcer. Training in the use of these scales is also required to ensure that ulcers are staged in a consistent manner.",
"   </p>",
"   <p>",
"    Ulcers heal through a process that includes granulation, wound contraction, reepithelialization, and scar formation. Thus, a stage 4 ulcer remains stage 4 throughout the healing process. The practice of changing the stage as the ulcer heals, known as reverse staging, is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate pain relief should be provided as pressure ulcers can be quite painful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/12\">",
"     12",
"    </a>",
"    ]. Initial and on-going pain assessment should be documented using a pain scale. Assessment is aimed at identifying the type and extent of pain present so that appropriate therapy may be provided. Pain may be classified as intermittent, which occurs at the time of wound debridement, or cyclic, which occurs at the time of a dressing change, or as persistent pain occurring all the time and realted to the pressure ulcer. &nbsp;",
"   </p>",
"   <p>",
"    Local factors that may be contributing to pain such as ischemia, infection, or breakdown of the surrounding skin should be addressed.",
"   </p>",
"   <p>",
"    Simple oral non-opioids can be used for mild pain. Opioid analgesics may be needed for moderate to severe pain. Guidelines for managing cancer pain can be helpful in the setting of pressure ulcers as well . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical local anesthetics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    can provide numbness for a short period of time and can be useful for a specific procedure, but should not be used as the only method of pain relief . Topical opioid preparations have shown some benefit in small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Ibuprofen-releasing foam dressings can be used, if available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/16\">",
"     16",
"    </a>",
"    ]. However, most patients will require systemic therapy for pain from pressure ulcers.",
"   </p>",
"   <p>",
"    Wound cleansing and dressing techniques may need to be reconsidered if they are causing severe pain. In particular, adequate pain control should be provided for dressing changes and debridement. Extensive debridement should be performed in the operating room as patients may require conscious sedation or general anesthesia for these invasive procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Assess and optimize nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pressure ulcers are in a chronic catabolic state. Optimizing both protein and total caloric intake is important, particularly for patients with stage 3 and 4 ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nutritional intake should be assessed by a nutritionist. This assessment may include protein and caloric intake, hydration status, serum albumin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prealbumin, and total lymphocyte count [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/17\">",
"       17",
"      </a>",
"      ]. Nutritional deficiencies should be corrected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link\">",
"       \"Nutrition support in critically ill patients: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If oral intake is not adequate to ensure sufficient calories, protein, vitamins, and minerals, nutritional supplementation with enteral and parenteral nutrition is recommended to correct deficiencies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. A retrospective cohort study of 882 patients with pressure ulcers at 95 long-term care facilities demonstrated that total caloric intake of at least 30",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      promoted healing and decreased the size of stage 3 and 4 pressure ulcers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/21\">",
"       21",
"      </a>",
"      ]. Increased dietary protein intake also promotes the healing of pressure ulcers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. The protein target is usually 1.5",
"      <span class=\"nowrap\">",
"       g/kg/day,",
"      </span>",
"      although some authors advocate higher protein intake [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data do not support nutritional supplementation for patients who do not have nutritional deficiencies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/24\">",
"       24",
"      </a>",
"      ]. Vitamin C and zinc supplementation are commonly employed to promote healing but their efficacy has not been conclusively demonstrated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/18\">",
"       18",
"      </a>",
"      ]. A number of small randomized trials have evaluated the role of nutritional supplements but methodological flaws and study size preclude confirmation of clinically significant results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/2,18\">",
"       2,18",
"      </a>",
"      ]. A propensity-matched cohort study of nursing home residents with advanced dementia demonstrated no improvements in pressure ulcer healing in patients with feeding tubes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mattresses and tissue pressure relief",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, there are no randomized trials available to identify whether repositioning makes a difference in the healing rates of pressure ulcers or what should be the optimal repositioning regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Nevertheless, in the absence of data, as a practice with good face value, patients should be positioned to minimize or avoid all pressure on the wound. Pressure-relieving support surfaces are also helpful in reducing tissue pressure. These support devices, as defined by the National Pressure Ulcer Advisory Panel Support Surface Standards Initiative, are outlined below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-powered support surfaces (previously known as static), such as foam, do not require electricity. These supports can be used if the patient can assume a variety of positions without bearing weight on the ulcer.",
"     </li>",
"     <li>",
"      Overlays are an additional support surface, designed to be placed on top of another support surface. Foam, air, or water overlays are useful for patients who can assume a variety of positions without bearing weight on the ulcer.",
"     </li>",
"     <li>",
"      Powered or dynamic support surfaces require electricity. Air currents or mechanical rotation regulate or redistribute pressure against the body. Examples of such beds include alternating pressure mattresses, low air loss beds, and air fluidized mattresses. Specialized powered beds should be considered when the patient cannot readily be repositioned, has a large ulcer or ulcers at multiple sites, or if the pressure ulcer does not show evidence of healing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of different specialized support surfaces has been studied in a number of randomized clinical trials with inconsistent results. However, none of the studies compared a specialized support surface with a standard mattress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 158 hospitalized patients found no difference in pressure ulcer healing between 85 patients on nonpowered support devices and 83 on powered support devices [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 65 hospitalized patients with pressure ulcers, 31 patients were given an air-fluidized bed and repositioned every four hours, while 34 patients received conventional therapy with an air mattress covered by a foam pad and repositioning every two hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/22\">",
"       22",
"      </a>",
"      ]. The latter group also used elbow or heel pads as needed. Pressure ulcers showed a median decrease in total surface area on the air-fluidized beds, while increasing in size with conventional therapy (-1.2 versus +0.5 cm2). The difference was even greater in patients with large ulcers at baseline.",
"     </li>",
"     <li>",
"      In another report of 84 nursing home residents with pressure ulcers, subjects treated with a low-air-loss bed were 2.5 times more likely to heal compared with those using a foam mattress [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given limited data, it is uncertain if powered mattresses are superior to non powered mattresses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/2\">",
"     2",
"    </a>",
"    ]. However, specialized support surfaces appear to be of benefit and should be used, when available, instead of a standard mattress. Specialized beds may be most important for selected patients in whom rapid healing of the pressure ulcer is critical in meeting overall treatment goals, such as a patient with a severe ulcer who could potentially be discharged home once the ulcer resolved. Powered beds do carry a high cost. The costs become particularly significant when considering that treatment for at least two months is typically required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should again be emphasized that support surfaces alone do not address the underlying issues that lead to pressure ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ULCER TREATMENT BY STAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used system, proposed by the National Pressure Ulcer Advisory Panel (NPUAP) is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34120?source=see_link&amp;anchor=H5#H5\">",
"     \"Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging\", section on '2007 NPUAP staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stage 1 treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of stage 1 ulcers is a warning that more serious lesions may follow if appropriate preventive measures are not instituted in a timely fashion. Stage 1 ulcers may be dressed with transparent films for protection. Most importantly, preventive measures should be reviewed and intensified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Stage 2 treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage 2 pressure ulcers usually require an occlusive or semipermeable dressing to maintain a moist wound environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/32\">",
"     32",
"    </a>",
"    ]. Wet-to-dry dressings are avoided since these wounds generally require little debridement. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Dressing choices'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Stages 3 and 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of wound infections, debridement of necrotic tissue, and appropriate dressings will accelerate healing of Stage 3 and 4 pressure ulcers. Surgery is necessary for some full thickness pressure ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Wound infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound infections will impair healing. The possible presence of an infection should be considered even if systemic signs, such as fever and leukocytosis, are absent. Infection of pressure ulcers often presents with local signs of soft tissue involvement, such as warmth, erythema, local tenderness, purulent discharge, and the presence of a foul odor. However, the manifestations of infection in pressure ulcers can be variable with delayed wound healing being the only sign of infection.",
"   </p>",
"   <p>",
"    The extent of infection in the bone or soft tissue surrounding the ulcer affects management. Treatment for infection may require local debridement, topical antibiotics, or systemic antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/9\">",
"     9",
"    </a>",
"    ]. In particular, patients with deep ulcers should be evaluated for the presence of osteomyelitis. The infectious complications of pressure ulcers including pathogenesis, microbiology and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31350?source=see_link\">",
"     \"Infectious complications of pressure ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dressing choices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dressings serve to protect the wound from trauma and contamination, and facilitate healing by absorption of exudate and protection of healing surfaces. Excess fluid causes wound maceration, while desiccation will slow epithelial cell migration.",
"   </p>",
"   <p>",
"    Many different types of dressings are available. Although varying circumstances may favor choosing one dressing over another, no dressing has been shown to be consistently superior to another in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/2,33,34\">",
"     2,33,34",
"    </a>",
"    ]. Factors to keep in mind while selecting an appropriate dressing include the presence of heavy exudate, desiccation, infected or necrotic tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Ulcers with heavy exudate",
"    </span>",
"    &nbsp;&mdash;&nbsp;An absorptive dressing should be employed to avoid build up of chronic wound fluid that can lead to wound maceration and inhibition of cell proliferation and healing. An appropriate wound dressing can remove excess wound exudate while maintaining a moist environment to accelerate wound healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dressings with absorptive qualities include alginates, foams, and hydrofibers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcium alginates are highly absorptive and are useful for wounds with significant exudate. Calcium alginates are derived from brown seaweed and form a gel on contact, promoting moist interactive healing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Foams provide thermal insulation, high absorbency, and a moist environment. They can be easily cut to shape and do not shed fibers. Foams are useful for sloughy or exudative wounds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hydrofibers can also be used for highly exudative wounds and are highly absorbent. They are appropriate for sloughy or exudative wounds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Desiccated ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desiccated ulcers lack wound fluids, which provide tissue growth factors to facilitate reepithelialization. Thus, pressure ulcer healing is promoted by dressings that maintain a moist wound environment while keeping the surrounding intact skin dry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/21,32,36\">",
"     21,32,36",
"    </a>",
"    ]. Choices for a dry wound include saline moistened gauze, transparent films, hydrocolloids, and hydrogels.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saline moistened gauze that is not allowed to dry will promote a moist wound environment, although occlusive dressings are equally effective and reduce the nursing time required for wound care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transparent films provide an effective barrier for retaining moisture; they are good secondary dressings when combined with another product for stage 3 or 4 ulcers (full thickness wounds) or may be used alone for stage 2 ulcers (partial thickness wounds). Films are especially useful at the later stages of wound healing when there is no significant exudate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hydrocolloids generally provide an effective barrier for retaining moisture and are useful for promoting autolytic debridement. They come in a variety of sizes and shapes for use on different parts of the body. A comparison randomized trial of transparent films with hydrocolloid dressing in the management of stage 2 and shallow stage 3 pressure ulcers demonstrated the transparent film dressing improved the ability to assess the ulcer and improved patient comfort although the time to wound closure was nearly identical between the two groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hydrogels provide a high concentration of water contained in insoluble polymers and provide a good choice for dry sloughy wounds with low levels of exudate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotic tissue promotes bacterial growth and impairs wound healing. Accordingly, it would seem that removal of necrotic tissue by wound debridement is an important element of pressure ulcer treatment. Randomized trials, however, compare different methods of debridement but have not focused on the effectiveness of debridement per se [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five approaches to debridement are available; they are often used in combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/12,35\">",
"     12,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sharp debridement involves the use of a scalpel or scissors. This is the most rapid form of debridement; it is indicated when there is evidence of cellulitis or sepsis. Sharp debridement is also used to remove thick eschar and when there is extensive necrotic tissue. The exception is patients with heel ulcers covered by a thick, dry eschar, particularly in the setting of a reduced perfusion. Sharp debridement is not recommended at this site, because of the proximity of bone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mechanical debridement is a nonselective method of removing necrotic tissue and debris from a wound. This is most commonly done with wet-to-dry dressings. Mechanical debridement is best for wounds that contain thick exudate, slough, or loose necrotic tissue. Wet-to-dry dressings will remove both nonviable and viable tissues; caution is required to avoid damaging healthy tissue.",
"     </li>",
"     <li>",
"      Enzymatic debridement is done with the topical application of proteolytic enzymes such as collagenase, fibrinolysin, and deoxyribonuclease to remove necrotic tissue. The topically applied enzymes work synergistically with endogenous enzymes to debride the wound. These agents may produce excess exudate and cause local irritation to the surrounding skin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/35,41-43\">",
"       35,41-43",
"      </a>",
"      ]. Papain was used for debridement in the past but was removed from the US market due to hypersensitivity reactions.",
"     </li>",
"     <li>",
"      Autolytic debridement uses semiocclusive (transparent film) or occlusive dressings (hydrocolloids or hydrogels) to cover a wound so that necrotic tissue is digested by enzymes normally present in wound tissue. This often works best on wounds with minimal exudate. It should not be used in the presence of infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/12,35,39\">",
"       12,35,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Biosurgery or the use of maggots is another effective method of debridement. The larvae produce enzymes to break down dead tissue without harming healthy tissue. This can be considered when sharp debridement is contraindicated due to exposed bone, joint, or tendon. Sterile larvae of the Lucilia sericata fly are utilized [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/12,35,44\">",
"       12,35,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Debridement should stop once necrotic tissue has been removed and granulation tissue is present. Care should be taken with respect to debridement of the ischial spine as this will potentially affect weightbearing and can lead to breakdown of the ischium on the opposite side. Removal of both ischial spines will increase the risk of perineal problems and the formation of urethrocutaneous fistulas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgery for wound closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pressure ulcers are successfully managed using the basic principles of wound care and dressings cited above. Two studies from large nursing home chains have collectively followed over 1000 pressure ulcer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Over 70 percent of patients with a stage 2 pressure ulcer, 50 percent with a stage 3 ulcer, and 30 percent with a stage 4 ulcer were ulcer-free at six months with conservative nonoperative management. In patients followed for two years, 77 percent of stage 4 ulcers had healed.",
"   </p>",
"   <p>",
"    Nevertheless, surgical wound closure is still necessary in some patients, particularly in those whose quality of life would be markedly improved by rapid wound closure. A variety of operative procedures are available, usually requiring staged procedures for skin grafts, skin flaps, musculocutaneous flaps, and free flaps. Direct wound closure is usually not possible. Procedure selection depends upon patient characteristics, ulcer site, and available surgical expertise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Procedures may last for up to three hours and result in considerable blood loss: patients must be medically stable prior to surgery. In addition, ulcers should be free of devitalized tissue, and patient factors predisposing to pressure ulcer development should be corrected where possible. Smokers should be encouraged to stop since continued smoking impairs wound healing and may result in higher rates of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Operative repair often results in wound closure, although the long-term efficacy is less certain. Ulcer recurrence rates of 13 to 61 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Thus, the role of operative repair is still uncertain for many patients. The decision to perform surgery depends upon patient preference, treatment goals, risk of recurrence, and quality of life considerations.",
"   </p>",
"   <p>",
"    A fecal diversion via surgical colostomy is occasionally considered to promote wound healing if the site of the ulcer is prone to fecal contamination. However, this procedure may be associated with a high complication rate in frail elderly patients and is of questionable efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Adjunctive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of adjunctive therapies such as electrical stimulation, negative pressure wound therapy, therapeutic ultrasound, hyperbaric oxygen, topical oxygen, and application of growth factors to the wound are being investigated for the treatment of pressure ulcers . Indications for their use remain uncertain. Some of these adjunctive therapies are discussed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Negative pressure wound therapy, also known as VAC therapy, enhances wound healing by reducing increasing blood flow, decreasing edema, and increasing the formation of granulation tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/27,51,52\">",
"       27,51,52",
"      </a>",
"      ]. Negative pressure wound therapy is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26264?source=see_link\">",
"       \"Negative pressure wound therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperbaric oxygen (HBO) therapy has been advocated, but its efficacy remains uncertain. There have been no studies specifically looking at the treatment of pressure ulcers with HBO. Systematic reviews of studies of HBO for treating wounds concluded that while HBO may be of benefit for some types of wounds, there is insufficient evidence of sustained benefit. The underlying study quality was poor; some serious adverse events were associated with HBO therapy including seizures and pneumothorax [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ultrasound is sometimes used as therapy for pressure ulcers. A systematic review of three randomized trials found that methodologic limitations and small trail size made it impossible to rule out benefit or harm with ultrasound therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Electrical stimulation, in which a direct current is applied to the wound, has also resulted in enhanced healing in several small studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/56,57\">",
"       56,57",
"      </a>",
"      ] and a meta-analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/58\">",
"       58",
"      </a>",
"      ]. The electric current is provided twice daily through a wound overlay and is believed to promote the migration and proliferation of fibroblasts. A systematic review of randomized trials of electromagnetic therapy, a distinct form of electrotherapy, found no evidence of benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/59\">",
"       59",
"      </a>",
"      ]. Similarly, pulsed radiofrequency energy therapy and electromagnetic therapy have been proposed but evidence of benefit is limited [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pressure ulcers or those who develop a new ulcer are approximately two to three times more likely to die than patients without an ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37064/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. However, patients with pressure ulcers tend to have many other comorbid conditions; after adjusting for these other factors, pressure ulcers are at best a weak predictor of mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/53/39761?source=see_link\">",
"       \"Patient information: Pressure sores (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of pressure ulcers begins with a comprehensive assessment of the patient's general medical condition and evaluation of the wound. A standardized system for staging pressure ulcers should be used to document initial presentation, plan appropriate treatment, and follow the healing progress of the wound. The development of an ulcer should underscore the need to review and intensify preventive measures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Assessment and staging'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34120?source=see_link\">",
"       \"Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Close daily monitoring of the pressure ulcer, the dressing, the surrounding skin, any possible complications and pain control should be documented. Documentation may be facilitated by using one of the scales for healing ulcers. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Healing Scales'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequate pain control should be provided for patients with pressure ulcers. Particular attention should be paid to pain management during wound dressing and debridement. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pain control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nutritional status should be assessed in patients with pressure ulcers and any identified deficiencies should be corrected. We suggest not giving nutritional supplementation for patients without documented nutritional deficiency (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Assess and optimize nutritional status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be positioned and repositioned at least every two hours to relieve tissue pressure. We suggest use of non-powered support surfaces (eg, foam mattresses or overlays) for most patients with pressure ulcers (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). When cost is not a limiting factor, powered surfaces (eg air-fluidized beds) may be appropriate for selected patients with large or multiple ulcers that preclude appropriate positioning. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mattresses and tissue pressure relief'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for stage 1 ulcers should focus on preventive measures and wound protection with transparent film. Stage 2 ulcers require dressings to maintain a moist wound environment. Stage 3 and 4 ulcers should be managed by treatment of wound infection if present, debridement of necrotic tissue, and appropriate dressings. Surgery is necessary for some full thickness pressure ulcers. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ulcer treatment by stage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dressings are selected, based on wound characteristics including the presence of heavy exudate, desiccation, or necrotic tissue. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Dressing choices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Necrotic tissue promotes bacterial growth and impairs wound healing. Wound debridement may involve any of five approaches: use of sharp dissection, mechanical debridement (wet-to-dry dressings), application of proteolytic enzymes, autolytic debridement under occlusive dressings, or biosurgery with sterilized maggots. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Debridement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients are successfully managed without surgery, procedures such as direct closure, skin grafts, musculocutaneous flaps, and free flaps may be appropriate in patients whose quality of life would be markedly improved by rapid wound closure. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Surgery for wound closure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/1\">",
"      Bauer J, Phillips LG. MOC-PSSM CME article: Pressure sores. Plast Reconstr Surg 2008; 121:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/2\">",
"      Reddy M, Gill SS, Kalkar SR, et al. Treatment of pressure ulcers: a systematic review. JAMA 2008; 300:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/3\">",
"      Thomas DR. The new F-tag 314: prevention and management of pressure ulcers. J Am Med Dir Assoc 2006; 7:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/4\">",
"      Bates-Jensen BM. The Pressure Sore Status Tool a few thousand assessments later. Adv Wound Care 1997; 10:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/5\">",
"      Thomas DR, Rodeheaver GT, Bartolucci AA, et al. Pressure ulcer scale for healing: derivation and validation of the PUSH tool. The PUSH Task Force. Adv Wound Care 1997; 10:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/6\">",
"      Ferrell BA. The Sessing Scale for measurement of pressure ulcer healing. Adv Wound Care 1997; 10:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/7\">",
"      Krasner D. Wound Healing Scale, version 1.0: a proposal. Adv Wound Care 1997; 10:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/8\">",
"      Moss RJ, La Puma J. The ethics of pressure sore prevention and treatment in the elderly: a practical approach. J Am Geriatr Soc 1991; 39:905.",
"     </a>",
"    </li>",
"    <li>",
"     Advisory Panel, European Pressure Ulcer Advisory Panel. Pressure ulcer treatment recommendations. In: Prevention and treatment of pressure ulcers: clinical practice guideline, National Pressure Ulcer Advisory Panel, Washington, DC 2009.",
"    </li>",
"    <li>",
"     www.npuap.org (Accessed on April 08, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/11\">",
"      National Pressure Ulcer Advisory Panel. NPUAP position on reverse staging of pressure ulcers. Adv Wound Care 1998; 8:32.",
"     </a>",
"    </li>",
"    <li>",
"     Lyder, CH, Ayello, EA. Chapter 12. Pressure ulcers: a patient safety issue. www.ahrq.gov/qual/nurseshdbk/docs/LyderC_PUPSI.pdf (Accessed on April 01, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/13\">",
"      Flock P. Pilot study to determine the effectiveness of diamorphine gel to control pressure ulcer pain. J Pain Symptom Manage 2003; 25:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/14\">",
"      Zeppetella G, Paul J, Ribeiro MD. Analgesic efficacy of morphine applied topically to painful ulcers. J Pain Symptom Manage 2003; 25:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/15\">",
"      Zeppetella G, Ribeiro MD. Morphine in intrasite gel applied topically to painful ulcers. J Pain Symptom Manage 2005; 29:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/16\">",
"      Arapoglou V, Katsenis K, Syrigos KN, et al. Analgesic efficacy of an ibuprofen-releasing foam dressing compared with local best practice for painful exuding wounds. J Wound Care 2011; 20:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/17\">",
"      Stechmiller JK, Cowan L, Whitney JD, et al. Guidelines for the prevention of pressure ulcers. Wound Repair Regen 2008; 16:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/18\">",
"      Langer G, Schloemer G, Knerr A, et al. Nutritional interventions for preventing and treating pressure ulcers. Cochrane Database Syst Rev 2003; :CD003216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/19\">",
"      Koretz RL, Avenell A, Lipman TO, et al. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol 2007; 102:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/20\">",
"      ter Riet G, Kessels AG, Knipschild PG. Randomized clinical trial of ascorbic acid in the treatment of pressure ulcers. J Clin Epidemiol 1995; 48:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/21\">",
"      Bergstrom N, Horn SD, Smout RJ, et al. The National Pressure Ulcer Long-Term Care Study: outcomes of pressure ulcer treatments in long-term care. J Am Geriatr Soc 2005; 53:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/22\">",
"      Allman RM, Walker JM, Hart MK, et al. Air-fluidized beds or conventional therapy for pressure sores. A randomized trial. Ann Intern Med 1987; 107:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/23\">",
"      Breslow RA, Hallfrisch J, Guy DG, et al. The importance of dietary protein in healing pressure ulcers. J Am Geriatr Soc 1993; 41:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/24\">",
"      Lyder CH. Pressure ulcer prevention and management. JAMA 2003; 289:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/25\">",
"      Teno JM, Gozalo P, Mitchell SL, et al. Feeding tubes and the prevention or healing of pressure ulcers. Arch Intern Med 2012; 172:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/26\">",
"      Moore ZE, Cowman S. Repositioning for treating pressure ulcers. Cochrane Database Syst Rev 2012; 9:CD006898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/27\">",
"      Levine SM, Sinno S, Levine JP, Saadeh PB. Current thoughts for the prevention and treatment of pressure ulcers: using the evidence to determine fact or fiction. Ann Surg 2013; 257:603.",
"     </a>",
"    </li>",
"    <li>",
"     National Pressure Ulcer Advisory Panel Support Surface Standards Initiative. Terms and definitions related to support surfaces. www.npuap.org/NPUAP_S3I_TD.pdf (Accessed on April 07, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/29\">",
"      Russell L, Reynolds TM, Towns A, et al. Randomized comparison trial of the RIK and the Nimbus 3 mattresses. Br J Nurs 2003; 12:254, 256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/30\">",
"      Ferrell BA, Osterweil D, Christenson P. A randomized trial of low-air-loss beds for treatment of pressure ulcers. JAMA 1993; 269:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/31\">",
"      Bennett RG, Bellantoni MF, Ouslander JG. Air-fluidized bed treatment of nursing home patients with pressure sores. J Am Geriatr Soc 1989; 37:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/32\">",
"      Sebern MD. Pressure ulcer management in home health care: efficacy and cost effectiveness of moisture vapor permeable dressing. Arch Phys Med Rehabil 1986; 67:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/33\">",
"      Graumlich JF, Blough LS, McLaughlin RG, et al. Healing pressure ulcers with collagen or hydrocolloid: a randomized, controlled trial. J Am Geriatr Soc 2003; 51:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/34\">",
"      Bluestein D, Javaheri A. Pressure ulcers: prevention, evaluation, and management. Am Fam Physician 2008; 78:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/35\">",
"      Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen 2003; 11 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/36\">",
"      Gorse GJ, Messner RL. Improved pressure sore healing with hydrocolloid dressings. Arch Dermatol 1987; 123:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/37\">",
"      Alm A, Hornmark AM, Fall PA, et al. Care of pressure sores: a controlled study of the use of a hydrocolloid dressing compared with wet saline gauze compresses. Acta Derm Venereol Suppl (Stockh) 1989; 149:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/38\">",
"      Xakellis GC, Chrischilles EA. Hydrocolloid versus saline-gauze dressings in treating pressure ulcers: a cost-effectiveness analysis. Arch Phys Med Rehabil 1992; 73:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/39\">",
"      Brown-Etris M, Milne C, Orsted H, et al. A prospective, randomized, multisite clinical evaluation of a transparent absorbent acrylic dressing and a hydrocolloid dressing in the management of Stage II and shallow Stage III pressure ulcers. Adv Skin Wound Care 2008; 21:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/40\">",
"      Dryburgh N, Smith F, Donaldson J, Mitchell M. Debridement for surgical wounds. Cochrane Database Syst Rev 2008; :CD006214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/41\">",
"      Rao DB, Sane PG, Georgiev EL. Collagenase in the treatment of dermal and decubitus ulcers. J Am Geriatr Soc 1975; 23:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/42\">",
"      Lee LK, Ambrus JL. Collagenase therapy for decubitus ulcers. Geriatrics 1975; 30:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/43\">",
"      P&uuml;llen R, Popp R, Volkers P, F&uuml;sgen I. Prospective randomized double-blind study of the wound-debriding effects of collagenase and fibrinolysin/deoxyribonuclease in pressure ulcers. Age Ageing 2002; 31:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/44\">",
"      Whitaker IS, Twine C, Whitaker MJ, et al. Larval therapy from antiquity to the present day: mechanisms of action, clinical applications and future potential. Postgrad Med J 2007; 83:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/45\">",
"      Brandeis GH, Morris JN, Nash DJ, Lipsitz LA. The epidemiology and natural history of pressure ulcers in elderly nursing home residents. JAMA 1990; 264:2905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/46\">",
"      Berlowitz DR, Brandeis GH, Anderson J, Brand HK. Predictors of pressure ulcer healing among long-term care residents. J Am Geriatr Soc 1997; 45:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/47\">",
"      Niazi ZB, Salzberg CA, Byrne DW, Viehbeck M. Recurrence of initial pressure ulcer in persons with spinal cord injuries. Adv Wound Care 1997; 10:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/48\">",
"      Disa JJ, Carlton JM, Goldberg NH. Efficacy of operative cure in pressure sore patients. Plast Reconstr Surg 1992; 89:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/49\">",
"      Mandrekas AD, Mastorakos DP. The management of decubitus ulcers by musculocutaneous flaps: a five-year experience. Ann Plast Surg 1992; 28:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/50\">",
"      Deshmukh GR, Barkel DC, Sevo D, Hergenroeder P. Use or misuse of colostomy to heal pressure ulcers. Dis Colon Rectum 1996; 39:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/51\">",
"      Ubbink DT, Westerbos SJ, Evans D, et al. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev 2008; :CD001898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/52\">",
"      Ford CN, Reinhard ER, Yeh D, et al. Interim analysis of a prospective, randomized trial of vacuum-assisted closure versus the healthpoint system in the management of pressure ulcers. Ann Plast Surg 2002; 49:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/53\">",
"      Wang C, Schwaitzberg S, Berliner E, et al. Hyperbaric oxygen for treating wounds: a systematic review of the literature. Arch Surg 2003; 138:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/54\">",
"      Kranke P, Bennett MH, Martyn-St James M, et al. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2012; 4:CD004123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/55\">",
"      Flemming K, Cullum N. Therapeutic ultrasound for pressure sores. Cochrane Database Syst Rev 2000; :CD001275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/56\">",
"      Griffin JW, Tooms RE, Mendius RA, et al. Efficacy of high voltage pulsed current for healing of pressure ulcers in patients with spinal cord injury. Phys Ther 1991; 71:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/57\">",
"      Feedar JA, Kloth LC, Gentzkow GD. Chronic dermal ulcer healing enhanced with monophasic pulsed electrical stimulation. Phys Ther 1991; 71:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/58\">",
"      Gardner SE, Frantz RA, Schmidt FL. Effect of electrical stimulation on chronic wound healing: a meta-analysis. Wound Repair Regen 1999; 7:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/59\">",
"      Flemming K, Cullum N. Electromagnetic therapy for the treatment of pressure sores. Cochrane Database Syst Rev 2001; :CD002930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/60\">",
"      Conner-Kerr T, Isenberg RA. Retrospective analysis of pulsed radiofrequency energy therapy use in the treatment of chronic pressure ulcers. Adv Skin Wound Care 2012; 25:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/61\">",
"      Thomas DR, Goode PS, Tarquine PH, Allman RM. Hospital-acquired pressure ulcers and risk of death. J Am Geriatr Soc 1996; 44:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/62\">",
"      Berlowitz DR, Wilking SV. The short-term outcome of pressure sores. J Am Geriatr Soc 1990; 38:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37064/abstract/63\">",
"      Berlowitz DR, Brandeis GH, Anderson J, et al. Effect of pressure ulcers on the survival of long-term care residents. J Gerontol A Biol Sci Med Sci 1997; 52:M106.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2887 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37064=[""].join("\n");
var outline_f36_12_37064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASSESSMENT AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL TREATMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Healing Scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pain control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Assess and optimize nutritional status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mattresses and tissue pressure relief",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ULCER TREATMENT BY STAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stage 1 treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Stage 2 treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Stages 3 and 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Wound infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dressing choices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Ulcers with heavy exudate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Desiccated ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Debridement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgery for wound closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Adjunctive therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2887\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2887|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/46/29415\" title=\"figure 1\">",
"      Pressure ulcer sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/1/19480\" title=\"figure 2\">",
"      Characteristics of pressure ulcers by stage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2887|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/62/21483\" title=\"table 1\">",
"      Staging of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/13/31964\" title=\"table 2\">",
"      Pressure Ulcer Scale for Healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/43/39612\" title=\"table 3\">",
"      Pressure sore status tool",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31350?source=related_link\">",
"      Infectious complications of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/53/39761?source=related_link\">",
"      Patient information: Pressure sores (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/20/34120?source=related_link\">",
"      Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1049?source=related_link\">",
"      Prevention of pressure ulcers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_12_37065="Treatment and prognosis of adolescent idiopathic scoliosis";
var content_f36_12_37065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of adolescent idiopathic scoliosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37065/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37065/contributors\">",
"     Susan A Scherl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37065/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37065/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37065/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/12/37065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scoliosis is defined as a lateral curvature of the spine that is usually accompanied by rotation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62029 \" href=\"mobipreview.htm?23/58/24494\">",
"     image 1",
"    </a>",
"    ). Scoliosis is not a diagnosis, but a description of a structural alteration that occurs in a variety of conditions. Progression of the curvature during periods of rapid growth may result in significant deformity, which may be accompanied by cardiopulmonary compromise.",
"   </p>",
"   <p>",
"    The treatment and prognosis of adolescent idiopathic scoliosis will be reviewed here. The clinical features, diagnosis, and initial evaluation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=see_link\">",
"     \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the treatment of adolescent idiopathic scoliosis (AIS) is a curve with a Cobb angle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51712 \" href=\"mobipreview.htm?14/46/15087\">",
"     image 2",
"    </a>",
"    ) of 40&ordm; or less at skeletal maturity. Curves with Cobb angles greater than 50&ordm; at skeletal maturity may progress approximately one degree per year after cessation of growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/1\">",
"     1",
"    </a>",
"    ]. Over 30 years, such curves may progress to &gt;80&ordm;. Thoracic curves of this severity have been associated with restrictive lung disease and compromised pulmonary function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options for treatment include observation, bracing, and surgery, as discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. There is a lack of high-quality evidence from randomized trials that physical therapy (scoliosis specific exercises), chiropractic treatment, electrical stimulation, or biofeedback is effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of therapy depends upon the degree of curvature (as measured by the Cobb angle) and potential for further growth (which determines the risk for progression). Potential for further growth can be estimated by a combination of chronologic age, menarchal status in girls, skeletal maturity, and the Risser sign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Skeletal growth is considered complete in girls two years postmenarche and in boys when daily shaving is needed. Girls are considered skeletally mature at Risser 4 and boys at Risser 5. Finally, the cessation of height gains is a concrete sign of the end of growth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\", section on 'Risk for progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for AIS is individualized for each patient depending upon the best estimate of his or her risk for progression. Because it is not possible to predict with complete certainty which curves will progress and which will not, and because each patient may place a different value on the potential risks and benefits of the various treatment options, individual patient preferences must be taken into consideration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General guidelines for management of AIS at the time of presentation are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with angles of trunk rotation of &lt;7&ordm; (as measured by the scoliometer) (",
"      <a class=\"graphic graphic_picture graphicRef57756 \" href=\"mobipreview.htm?33/0/33806\">",
"       picture 1",
"      </a>",
"      ) are followed clinically (approximately every six months, depending upon growth potential) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/15\">",
"       15",
"      </a>",
"      ]. Radiographs (standing, full-length posteroanterior (PA) views of the spine exposed on a single long film cassette) should be obtained if the angle of trunk rotation increases to &ge;7&ordm;. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\", section on 'Radiographic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with Cobb angles of &lt;20&ordm; at the time of presentation may be observed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Observation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with substantial growth remaining (Risser sign 0 to 2) with Cobb angles of 20&ordm; to 29&ordm; are followed closely and are braced if they exhibit progression (an increase in Cobb angle of &ge;5&ordm; over a three- to six-month time period).",
"     </li>",
"     <li>",
"      Patients with substantial growth remaining (Risser sign 0 to 2) with Cobb angles of 30&ordm; to 40&ordm; are usually braced. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Bracing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with substantial growth remaining (Risser sign 0 to 2) with Cobb angles between 40&ordm; and 50&ordm; may be managed with bracing or surgery. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgery'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with substantial growth remaining (Risser sign 0 to 2) with Cobb angles of &gt;50&ordm; at the time of diagnosis usually require surgical intervention. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgery'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients at Risser sign 3 and above should be followed for at least a year past skeletal maturity (Risser 4 in girls, Risser 5 in boys) with radiographs every six to nine months. Skeletally mature patients with curves with Cobb angle &lt;40&ordm; can be reassured and discharged, with no need for regular follow-up. Skeletally mature patients with curves between 40&ordm; and 50&ordm; are assessed and managed on an individual basis. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Follow-up'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Referral indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents with curves at low risk for progression, and in whom an underlying congenital or neuromuscular cause has been excluded, may be followed by their primary care provider if the provider feels comfortable doing so. Indications for referral to an orthopedic surgeon may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angle of trunk rotation (as measured with the scoliometer) of &ge;7&ordm; and inability to obtain a Cobb angle",
"     </li>",
"     <li>",
"      Cobb angle between 20&ordm; and 29&ordm; in premenarcheal girls or boys aged 12 to 14 years",
"     </li>",
"     <li>",
"      Cobb angle &gt;30&ordm; in any patient",
"     </li>",
"     <li>",
"      Progression of Cobb angle of more than 5&ordm; in any patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some orthopedic surgeons suggest referral of all patients with Cobb angle &gt;20&ordm;, particularly if the patient or parents have questions that are beyond the scope of the primary care provider.",
"   </p>",
"   <p>",
"    At the time of referral, it is important to specify which method of measurement is being used to describe the curve, Cobb angle or scoliometer (angle of trunk rotation), because they are not directly equivalent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OBSERVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Cobb angles of less than 20&ordm; (or an angle of trunk rotation &lt;7&ordm;) may be observed and followed clinically every six to nine months by the primary care provider if the provider feels comfortable doing so. Younger children with more growth remaining and potential for curve progression should be followed more frequently than older children. Curves of this magnitude may progress approximately one degree per month during the adolescent growth spurt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limited added benefit of serial radiographs for observation of small curves must be balanced against the cost and cumulative radiation exposure. If ordered, follow-up radiographs should include standing, full-length posteroanterior (PA) views of the spine exposed on a single long film cassette. The lateral view need not be repeated if the initial radiograph demonstrated the normal configuration of thoracic kyphosis and lumbar lordosis.",
"   </p>",
"   <p>",
"    If, at the time of follow-up, the Cobb angle has progressed by &ge;5&ordm;, treatment may be indicated, and a referral should be made. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Bracing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BRACING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bracing does not correct curvature that is present at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/20-22\">",
"     20-22",
"    </a>",
"    ], but may prevent curve progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/14,23-26\">",
"     14,23-26",
"    </a>",
"    ], and thus may reduce the need for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/27\">",
"     27",
"    </a>",
"    ] (although this contention is disputed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]). Because the objective of bracing is prevention of curve progression, bracing is indicated only for skeletally immature patients (Risser sign 0 to 2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Indications and contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for bracing may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skeletally immature (Risser sign 0 to 2) patients whose Cobb angle is 30&ordm; to 40&ordm; at the time of presentation",
"     </li>",
"     <li>",
"      Skeletally immature patients whose curve progresses &ge;5&ordm; over any six- to nine-month period during observation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contraindications to bracing include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skeletal maturity (Risser sign 4 to 5 and ring apophyses fused)",
"     </li>",
"     <li>",
"      Cobb angle &ge;50&ordm;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the presence of thoracic lordosis is a relative contraindication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/33\">",
"     33",
"    </a>",
"    ]. Some authors maintain that thoracic lordosis is a component of all structural scolioses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Types",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most curves can be managed with an underarm brace (a thoraco-lumbar-sacral orthosis, TLSO, also known as the Boston brace) (",
"    <a class=\"graphic graphic_picture graphicRef62578 \" href=\"mobipreview.htm?35/7/35966\">",
"     picture 2",
"    </a>",
"    ). The TLSO can be camouflaged relatively easily under clothing and is fairly well accepted by most patients. Other types of underarm braces include the Charleston brace and the Providence braces, which are designed to be worn only at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. A nonrigid brace (SpineCor), which consists of a series of straps, is also available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small percentage of curves require a brace with an under-chin extension (a cervico-thoraco-lumbar-sacral orthosis, CTLSO, also known as the Milwaukee brace). The CTLSO is more difficult to hide under clothes and is understandably less well tolerated by patients. Indications for CTLSO bracing include thoracic curve with apex at or above T8, double thoracic curves (high-left and lower-right thoracic curve pattern and right",
"    <span class=\"nowrap\">",
"     thoracic/left",
"    </span>",
"    thoracolumbar pattern) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\", section on 'Curve pattern'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Efficacy of bracing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonrandomized studies of bracing for adolescent idiopathic scoliosis (AIS) have had mixed results, with some studies demonstrating a benefit compared with patients treated with observation or other nonsurgical therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/21,23,26,39,40\">",
"     21,23,26,39,40",
"    </a>",
"    ], and other studies or reviews calling those results into question [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/2,41-46\">",
"     2,41-46",
"    </a>",
"    ]. Data regarding the efficacy of the different types of braces also are mixed; differing inclusion criteria preclude direct comparisons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/30,47,48\">",
"     30,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies demonstrating an effect of bracing have been criticized for failure to consider the sex of the patients and having follow-up periods too short to detect deterioration after discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/28\">",
"     28",
"    </a>",
"    ]. In one long-term retrospective review of 110 patients who were treated for AIS with bracing, the average deterioration of curve over 22 years of follow-up was 7.8&ordm; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/49\">",
"     49",
"    </a>",
"    ]. Some authors suggest that bracing prevents progression during the time that the brace is worn but that after the brace is discontinued, the curve progresses to a level predetermined by unknown factors and eventually is unaffected by orthotic treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic reviews of nonoperative treatments for AIS have reached different conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/29,48,50,51\">",
"     29,48,50,51",
"    </a>",
"    ]. One found bracing to be more successful than observation or lateral electrical surface stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/48\">",
"     48",
"    </a>",
"    ]. However, this analysis has been criticized on a number of counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/50,52,53\">",
"     50,52,53",
"    </a>",
"    ]. Other systematic reviews found the evidence inconclusive or of very low quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/29,50,51\">",
"     29,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A five-year multicenter prospective randomized trial comparing bracing and observation in skeletally immature patients with Cobb angles between 25&ordm; and 40&ordm; is underway. The",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00448448\">",
"     Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)",
"    </a>",
"    , sponsored by the National Institutes of Health, involves 20 clinical centers in the United States and Canada. The study is ongoing but no longer recruiting participants.",
"   </p>",
"   <p>",
"    The efficacy of bracing appears to be directly related to the number of hours per day that the brace is worn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/23,54\">",
"     23,54",
"    </a>",
"    ]. In one meta-analysis, the weighted mean proportion of success was 0.93, 0.62, and 0.60 for 23, 16, and 8 hours of wear per day, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/48\">",
"     48",
"    </a>",
"    ]. The efficacy of bracing also appears to be related to sex (decreased in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/55\">",
"     55",
"    </a>",
"    ]), and weight (decreased in overweight patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/56\">",
"     56",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Duration of use",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hours per day",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is usually recommended that the brace be worn for 23 hours per day, since brace efficacy is directly related to time worn, as described in the preceding section. The brace may be removed for certain sports that cannot be performed while wearing it (eg, swimming, gymnastics), but many sports can be played while wearing the brace, which is preferable.",
"   </p>",
"   <p>",
"    Patients may not adhere to the 23-hour schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/54,57\">",
"     54,57",
"    </a>",
"    ]. In one retrospective review, the actual number of hours the brace was worn was less than that reported by patients at clinic visits and, on average, only 65 percent of the prescribed time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/54\">",
"     54",
"    </a>",
"    ]. In another study where adherence was monitored objectively with a hidden temperature sensor, braces were worn for an average of 65 percent of the prescribed hours (range 8 to 80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/57\">",
"     57",
"    </a>",
"    ]. Awareness of monitoring may increase adherence. In a small randomized trial, adherence to an 18-hour schedule was greater among patients who were told that their adherence was being monitored with a temperature sensor than among those who were not told (85.7 percent versus 56.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brace use should be continued until the end of growth, typically one to two years postmenarche with a Risser grade 4 to 5 for girls, and until a Risser grade 5 for boys. Some practitioners wean brace usage to nighttime (sleeping) only, and some simply discontinue it.",
"   </p>",
"   <p>",
"    Patients typically are seen in follow-up six months after discontinuation of the brace and then yearly for several years. There is often a several-degree \"collapse\" of the curve in the months just following discontinuation of the brace, which quickly stabilizes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are treated with braces should be assessed immediately after the first fitting to determine appropriate pad placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/4\">",
"     4",
"    </a>",
"    ]. An in-brace radiograph should be obtained to determine curve correction. Patients whose in-brace Cobb angle is at least 20 percent lower than the pre-brace Cobb angle measurement have an increased chance of successful bracing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, brace treatment should be monitored clinically and radiographically every six to eight months. During these visits, brace fit should be assessed, and radiographs (out of brace) should be obtained to assess curve progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/4\">",
"     4",
"    </a>",
"    ]. Progression of the Cobb angle of &ge;5&ordm; despite adequate bracing (properly fitting and worn according to schedule) is a poor prognostic sign that surgery may be necessary. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of bracing may include psychosocial effects with diminished self-esteem and disturbed peer relationships [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/32,44,59,60\">",
"     32,44,59,60",
"    </a>",
"    ]. In addition, patients with braces may develop skin irritation, have disturbed sleep, restriction of physical and recreational activities, and difficulty finding clothes that fit properly, although studies demonstrating the frequency of these effects are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/60\">",
"     60",
"    </a>",
"    ]. There has been a single case report of compressive injury to the dorsal scapular nerve resulting in scapular winging in 15-year-old girl after incorrect use of a thoracolumbar orthosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of surgical treatment of adolescent idiopathic scoliosis (AIS) is prevention of curve progression through spinal fusion; partial curve correction (a secondary goal) also is frequently achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical correction is indicated for skeletally immature patients presenting with curves with Cobb angle &ge;50&ordm; and some skeletally immature patients with Cobb angle between 40&ordm; and 50&ordm;. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common surgical procedure for AIS is a posterior spinal fusion (PSF) with instrumentation and bone grafting. The instrumentation used for PSF has evolved significantly since the 1970s. The original implants, called Harrington rods, were straight stainless steel rods connected to the cephalad and caudad regions of the spine with simple hooks. Contemporary implants are \"segmental\". Segmental instrumentation consists of a variety of hooks, screws, and wires that can be used to attach contoured rods to the spine at multiple vertebrae, or \"segments\", which affords the surgeon greater control over positioning and rotation of the spine (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70369 \" href=\"mobipreview.htm?31/24/32136\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/62\">",
"     62",
"    </a>",
"    ]. The increased stability of segmental instrumentation permits early mobilization with ambulation the day after surgery without external support such as a body cast or brace.",
"   </p>",
"   <p>",
"    Anterior instrumentation and fusion may be performed for thoraco-lumbar and lumbar scoliosis. The convex side of the spine is exposed anteriorly (often with the assistance of a general surgeon) by a thoracotomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retroperitoneal approach. The curve is corrected by shortening the convex side of the deformity. The purported advantages of the anterior approach include less blood loss, lower risk of neurologic injury (because of correction by shortening instead of distraction), and no disturbance of the paraspinal muscles. Disadvantages include increased complexity and decreased pulmonary function if the thoracic cavity is entered",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the diaphragm is opened [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/63\">",
"     63",
"    </a>",
"    ]. In a retrospective comparison, patients treated with posterior instrumentation and fusion for lumbar curves had better outcomes and shorter hospital stays than those treated with anterior instrumentation and fusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few surgeons have reported on anterior instrumentation of the thoracic spine using instrumentation inserted through several small incisions thoracoscopically. The potential advantages of video-assisted thoracoscopic surgery over posterior spinal fusion with thoracic pedicle screws include reduced blood loss, fewer total levels fused, and the preservation of nearly one caudad fusion level. The disadvantages include increased operative times and slightly less improvement in pulmonary function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/65\">",
"     65",
"    </a>",
"    ]. Thorascopic anterior instrumentation is technically demanding and applicable to a limited number of curves.",
"   </p>",
"   <p>",
"    Achieving bony fusion is the most important aspect of the surgery, and either autograft or allograft may be used for this purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/66\">",
"     66",
"    </a>",
"    ]. Routine use of bone morphogenic protein (BMP) is not indicated. In older patients with very stiff curves, it is sometimes necessary to release the anterior intervertebral soft tissues before PSF. This can sometimes be done thoracoscopically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/67\">",
"     67",
"    </a>",
"    ]. In patients with open tri-radiate cartilages, it is sometimes necessary to perform an anterior spinal fusion (ASF), as well as a PSF, to prevent the \"crankshaft phenomenon\", in which the anterior spine continues to grow after the PSF, causing a severe rotational and sagittal alignment deformity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, there is some evidence to suggest that modern segmental instrumentation systems make anterior fusion unnecessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Efficacy of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of surgical treatment of AIS is prevention of curve progression through spinal fusion, but there is limited evidence regarding this outcome. Successful fusion occurs in approximately 95 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary goals include curve correction and improved quality of life. In a meta-analysis, the average coronal curve correction ranged from 48 to 67 percent with posterior instrumentation, and 71 to 93 percent with anterior instrumentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/72\">",
"     72",
"    </a>",
"    ]. In a multicenter study of the outcomes of surgical treatment, patients reported improved self-image, function, and level of activity on validated measures two years after surgery for AIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pre-op evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the usual history and physical examination, preoperative assessment consists of posteroanterior and lateral spinal radiographs, bending films for surgical planning, and pulmonary function tests for patients with curves &ge;60&ordm;. Many surgeons recommend preoperative autologous blood donation and also require a pregnancy test in menarchal girls prior to surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of surgery include blood loss, infection, implant failure, neurologic injury, and pseudoarthrosis (failure of fusion). Because of the risk of blood loss, many centers provide appropriate patients the option of autologous blood donation before surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27832?source=see_link&amp;anchor=H12#H12\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Autologous donations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Modifications in devices, techniques, and intraoperative monitoring have reduced the risk of catastrophic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/34,74,75\">",
"     34,74,75",
"    </a>",
"    ]. Irreversible neurologic injury occurred in approximately 1 in 1000 cases before the use of intraoperative somatosensory and motor-evoked potential monitoring; the use of these interventions has decreased the risk to 1 in 7000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/34\">",
"     34",
"    </a>",
"    ]. Neurologic function must be monitored closely for 48 hours after surgery, since delayed neurologic injury may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of the morbidity and mortality database of the Scoliosis Research Society provides the following observations regarding the incidence and type of short-term complications of surgery for AIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      6334 patients underwent PSF, ASF, or combined spinal fusion with instrumentation for AIS during the period from 2001 to 2003.",
"     </li>",
"     <li>",
"      Complications were reported in 5.7 percent of patients overall; the rate of complications among patients with combined spinal fusion was twice that of patients who underwent either PSF or ASF (10.2 versus 5.2 and 5.1 percent, respectively).",
"     </li>",
"     <li>",
"      Pulmonary complications other than pulmonary embolus occurred in 1.0, 1.6 percent, and 3.5 percent of patients undergoing PSF, ASF, and combined spinal fusion, respectively.",
"     </li>",
"     <li>",
"      Wound infection occurred in 1.4, 0.2, and 1.4 percent of patients undergoing PSF, ASF, and combined spinal fusion, respectively.",
"     </li>",
"     <li>",
"      Incomplete spinal cord injuries occurred in 18 patients total (nine each in the PSF and combined spinal fusion groups, respectively). Among the nine patients in the PSF group, seven had complete recovery, and two had incomplete recovery. Among the nine patients in the combined spinal fusion group, four patients had complete recovery, four patients had incomplete recovery, and one patient had no recovery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term surgical complications were described in a retrospective review of patients who underwent surgical or brace treatment and were followed for 22 to 23 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/49\">",
"     49",
"    </a>",
"    ]. Among those surgically treated, the average curve deterioration was 3.5&ordm;; pseudoarthrosis developed in 1.9 percent of patients, and flat-back syndrome (loss of lumbar lordosis) in 2.6 percent; and 5.1 percent needed additional surgery related to implants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Activity restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for resuming participation in sports vary by surgeon, from as little as 4 months to 12 months postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/4,78,79\">",
"     4,78,79",
"    </a>",
"    ]. Once the spine has fused, all sports are permitted, with the possible exception of collision sports (eg, football, hockey, rugby). The reduced motion of the fused spine may make it more difficult to perform activities such as gymnastics and dancing at a high level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H449313343\">",
"    <span class=\"h2\">",
"     Metal detectors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The instrumentation may cause a problem at airport security. In the post",
"    <span class=\"nowrap\">",
"     9/11",
"    </span>",
"    era, a letter discussing the implants is of no value. Most surgeons warn patients with implants to plan on extra time when going through security. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the long-term outcomes of adolescent idiopathic scoliosis (AIS) treated with observation, bracing, or surgery. Because surgical methods change with time, the longer-term outcomes for patients treated surgically reflect",
"    <span class=\"nowrap\">",
"     procedures/implants",
"    </span>",
"    that are no longer being used. Twenty-year follow-up is available for patients treated with Harrington rods, but only 5- to 10-year follow-up for patients with segmental instrumentation.",
"   </p>",
"   <p>",
"    In one 50-year follow-up, untreated adults with AIS were productive and functioning at a high level. Untreated AIS resulted in little impairment other than back pain and cosmetic concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Curve progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scoliosis may continue to progress after skeletal maturity in untreated patients. In long-term studies, more than two-thirds of patients had curve progression after skeletal maturity. Progression of scoliosis after skeletal maturity was more likely with increased severity of scoliosis (curves of &lt;30&ordm; tended not to progress) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/1,81\">",
"     1,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Curves also may progress after bracing or surgery. In one study, patients who were treated with surgery or bracing were followed for an average of 22 to 23 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/49\">",
"     49",
"    </a>",
"    ]. Average coronal curve progression for patients treated with bracing and followed for 22 years was 7.9&ordm;. Average coronal curve progression for patients treated surgically and followed for 23 years was 3.5&ordm;.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up with the orthopedic surgeon typically is scheduled for up to two years after the onset of skeletal maturity (Risser 4 in girls, Risser 5 in boys). Most skeletally mature individuals with curves with Cobb angle &lt;40&ordm;",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    successful spinal fusion do not need routine follow-up into adulthood. Skeletally mature patients with curves with Cobb angle between 40&ordm; and 50&ordm; are assessed and managed on an individual basis. No consensus exists regarding the management of such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Back pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have demonstrated a slightly higher incidence of back pain among adults with AIS, whether treated or untreated compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/80,82-90\">",
"     80,82-90",
"    </a>",
"    ]. Some studies have demonstrated a correlation between the initial magnitude of the curve and subsequent complaints of back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Degenerative disc changes are more common among patients with AIS treated with bracing or surgery than among controls without AIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/49\">",
"     49",
"    </a>",
"    ]. Rates of disability among adults with a history of AIS have been increased compared with controls in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/83,91\">",
"     83,91",
"    </a>",
"    ], and similar in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Psychosocial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with age-matched controls, adolescents with AIS have increased suicidal thought and increased concerns related to body development and peer interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with AIS may have decreased perception of health status, even after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/86,89,93\">",
"     86,89,93",
"    </a>",
"    ]. In one review of outcomes 10 years after treatment for AIS, patients had moderately reduced perceived health status and activities of daily living compared with age-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/86\">",
"     86",
"    </a>",
"    ]. The patients treated surgically were less affected than those treated with bracing. In another study, at an average of 22 years after nonsurgical treatment for AIS, the perception of handicap was similar between AIS patients and controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy does not appear to affect curve progression, nor does scoliosis appear to affect pregnancy outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/14\">",
"     14",
"    </a>",
"    ]. Although early studies suggested that scoliotic curves progressed during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/94,95\">",
"     94,95",
"    </a>",
"    ], subsequent studies have demonstrated otherwise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. One study evaluated the effects of pregnancy in 355 patients with scoliosis and found that the risk of progression was not affected by the number of pregnancies, age at first pregnancy, or curve stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/96\">",
"     96",
"    </a>",
"    ]. Women with a history of AIS do not appear to have an increased risk of cesarean delivery or health problems during pregnancy compared with women without AIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/82,96,98\">",
"     82,96,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In long-term follow-up studies of patients with AIS, the mortality rate is not increased compared with that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/80,82\">",
"     80,82",
"    </a>",
"    ]. Increased mortality from cor pulmonale and right heart failure is seen only in patients with severe thoracic curves (&gt;90&ordm; to 100&ordm;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37065/abstract/25,80,82\">",
"     25,80,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/20/18754?source=see_link\">",
"       \"Patient information: Scoliosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of the treatment of adolescent idiopathic scoliosis (AIS) is a curve with a Cobb angle of 40&ordm; or less at skeletal maturity. Options for treatment include observation, bracing, and surgery. The choice of therapy depends upon the degree of curvature and potential for further growth. In addition, individual patient preferences must be taken into consideration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adolescents with curves at low risk for progression, and in whom an underlying congenital or neuromuscular cause has been excluded, may be followed by their primary care provider if the provider feels comfortable doing so. Indications for referral to an orthopedic surgeon may include angle of trunk rotation &ge;7&ordm; and inability to obtain a Cobb angle, Cobb angle between 20&ordm; and 29&ordm; in premenarcheal girls or boys aged 12 to 14 years, Cobb angle &gt;30&ordm; in any patient, and progression of Cobb angle &ge;5&ordm; in any patient. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Referral indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend observation for patients with Cobb angles of &lt;20&ordm; at the time of presentation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Skeletally immature patients who are observed are followed every six to nine months. Bracing may be indicated for skeletally immature patients whose Cobb angle increases by &ge;5&ordm; during observation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Observation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\", section on 'Natural history'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest observation for patients with Cobb angles of 20&ordm; to 29&ordm; at the time of presentation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Bracing may be indicated for patients with substantial growth remaining (Risser sign 0 to 2) if the Cobb angle increases by &ge;5&ordm; over a three- to six-month period. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest bracing for patients with substantial growth remaining (Risser sign 0 to 2) with Cobb angles of 30&ordm; to 40&ordm; at the time of presentation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients who are braced are monitored clinically and radiographically every six months. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Bracing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skeletally mature patients (Risser 4 in girls, Risser 5 in boys) with curves with Cobb angle &lt;40&ordm; can be reassured and discharged, with no need for regular follow-up. Skeletally mature patients with curves between 40&ordm; and 50&ordm; are assessed and managed on an individual basis. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery should be discussed for patients with Cobb angles &ge;50&ordm; at the time of presentation or later, regardless of the degree of skeletal maturity. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Outcome for patients with AIS is generally favorable, whether they are treated with observation, bracing, or surgery. They have a slightly increased risk of back pain and degenerative disc changes compared with patients without AIS, but have no increased risk of mortality or adverse pregnancy outcome. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/1\">",
"      Weinstein SL, Ponseti IV. Curve progression in idiopathic scoliosis. J Bone Joint Surg Am 1983; 65:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/2\">",
"      Screening for adolescent idiopathic scoliosis. Policy statement. US Preventive Services Task Force. JAMA 1993; 269:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/3\">",
"      Lonstein JE. Adolescent idiopathic scoliosis. Lancet 1994; 344:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/4\">",
"      Reamy BV, Slakey JB. Adolescent idiopathic scoliosis: review and current concepts. Am Fam Physician 2001; 64:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/5\">",
"      Skaggs DL, Bassett GS. Adolescent idiopathic scoliosis: an update. Am Fam Physician 1996; 53:2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/6\">",
"      Peterson LE, Nachemson AL. Prediction of progression of the curve in girls who have adolescent idiopathic scoliosis of moderate severity. Logistic regression analysis based on data from The Brace Study of the Scoliosis Research Society. J Bone Joint Surg Am 1995; 77:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/7\">",
"      Romano M, Minozzi S, Bettany-Saltikov J, et al. Exercises for adolescent idiopathic scoliosis. Cochrane Database Syst Rev 2012; 8:CD007837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/8\">",
"      Bylund P, Aaro S, Gottfries B, Jansson E. Is lateral electric surface stimulation an effective treatment for scoliosis? J Pediatr Orthop 1987; 7:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/9\">",
"      Wong MS, Mak AF, Luk KD, et al. Effectiveness of audio-biofeedback in postural training for adolescent idiopathic scoliosis patients. Prosthet Orthot Int 2001; 25:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/10\">",
"      Sanders JO, Khoury JG, Kishan S, et al. Predicting scoliosis progression from skeletal maturity: a simplified classification during adolescence. J Bone Joint Surg Am 2008; 90:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/11\">",
"      Little DG, Song KM, Katz D, Herring JA. Relationship of peak height velocity to other maturity indicators in idiopathic scoliosis in girls. J Bone Joint Surg Am 2000; 82:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/12\">",
"      Song KM, Little DG. Peak height velocity as a maturity indicator for males with idiopathic scoliosis. J Pediatr Orthop 2000; 20:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/13\">",
"      Sponseller PD. Sizing up scoliosis. JAMA 2003; 289:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/14\">",
"      Lonstein JE. Scoliosis: surgical versus nonsurgical treatment. Clin Orthop Relat Res 2006; 443:248.",
"     </a>",
"    </li>",
"    <li>",
"     Scoliosis. In: Essentials of Musculoskeletal Care, 2nd ed, Greene WB (Ed), American Academy of Orthopedic Surgeons, Rosemont, IL 2001. p.696.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/16\">",
"      Bunnell WP. Outcome of spinal screening. Spine (Phila Pa 1976) 1993; 18:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/17\">",
"      Grossman TW, Mazur JM, Cummings RJ. An evaluation of the Adams forward bend test and the scoliometer in a scoliosis school screening setting. J Pediatr Orthop 1995; 15:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/18\">",
"      Huang SC. Cut-off point of the Scoliometer in school scoliosis screening. Spine (Phila Pa 1976) 1997; 22:1985.",
"     </a>",
"    </li>",
"    <li>",
"     Sponseller PD. Bone, joint, and muscle problems. In: Oski's Pediatrics: Principles and Practice, 4th ed, McMillan JA, Feigin RD, DeAngelis CD, Jones MD Jr (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.2488.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/20\">",
"      Willers U, Normelli H, Aaro S, et al. Long-term results of Boston brace treatment on vertebral rotation in idiopathic scoliosis. Spine (Phila Pa 1976) 1993; 18:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/21\">",
"      Carr WA, Moe JH, Winter RB, Lonstein JE. Treatment of idiopathic scoliosis in the Milwaukee brace. J Bone Joint Surg Am 1980; 62:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/22\">",
"      Mellencamp DD, Blount WP, Anderson AJ. Milwaukee brace treatment of idiopathic scoliosis: late results. Clin Orthop Relat Res 1977; :47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/23\">",
"      Nachemson AL, Peterson LE. Effectiveness of treatment with a brace in girls who have adolescent idiopathic scoliosis. A prospective, controlled study based on data from the Brace Study of the Scoliosis Research Society. J Bone Joint Surg Am 1995; 77:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/24\">",
"      Grivas TB, Vasiliadis E, Chatziargiropoulos T, et al. The effect of a modified Boston brace with anti-rotatory blades on the progression of curves in idiopathic scoliosis: aetiologic implications. Pediatr Rehabil 2003; 6:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/25\">",
"      Pehrsson K, Larsson S, Oden A, Nachemson A. Long-term follow-up of patients with untreated scoliosis. A study of mortality, causes of death, and symptoms. Spine (Phila Pa 1976) 1992; 17:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/26\">",
"      Sanders JO, Newton PO, Browne RH, Herring AJ. Bracing in adolescent idiopathic scoliosis, surrogate outcomes, and the number needed to treat. J Pediatr Orthop 2012; 32 Suppl 2:S153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/27\">",
"      Rigo M, Reiter Ch, Weiss HR. Effect of conservative management on the prevalence of surgery in patients with adolescent idiopathic scoliosis. Pediatr Rehabil 2003; 6:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/28\">",
"      Dickson RA, Weinstein SL. Bracing (and screening)--yes or no? J Bone Joint Surg Br 1999; 81:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/29\">",
"      Dolan LA, Weinstein SL. Surgical rates after observation and bracing for adolescent idiopathic scoliosis: an evidence-based review. Spine (Phila Pa 1976) 2007; 32:S91.",
"     </a>",
"    </li>",
"    <li>",
"     Newton PO, Wenger DR. Idiopathic scoliosis. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RJ, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.693.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/31\">",
"      Nash CL Jr. Current concepts review: scoliosis bracing. J Bone Joint Surg Am 1980; 62:848.",
"     </a>",
"    </li>",
"    <li>",
"     Bright Futures Encounter Forms for Health Professionals. www.brightfutures.org/encounter/provider/index.html (Accessed on June 13, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/33\">",
"      Winter RB, Lovell WW, Moe JH. Excessive thoracic lordosis and loss of pulmonary function in patients with idiopathic scoliosis. J Bone Joint Surg Am 1975; 57:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/34\">",
"      Roach JW. Adolescent idiopathic scoliosis. Orthop Clin North Am 1999; 30:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/35\">",
"      Price CT, Scott DS, Reed FR Jr, et al. Nighttime bracing for adolescent idiopathic scoliosis with the Charleston Bending Brace: long-term follow-up. J Pediatr Orthop 1997; 17:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/36\">",
"      Janicki JA, Poe-Kochert C, Armstrong DG, Thompson GH. A comparison of the thoracolumbosacral orthoses and providence orthosis in the treatment of adolescent idiopathic scoliosis: results using the new SRS inclusion and assessment criteria for bracing studies. J Pediatr Orthop 2007; 27:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/37\">",
"      Lee CS, Hwang CJ, Kim DJ, et al. Effectiveness of the Charleston night-time bending brace in the treatment of adolescent idiopathic scoliosis. J Pediatr Orthop 2012; 32:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/38\">",
"      Gammon SR, Mehlman CT, Chan W, et al. A comparison of thoracolumbosacral orthoses and SpineCor treatment of adolescent idiopathic scoliosis patients using the Scoliosis Research Society standardized criteria. J Pediatr Orthop 2010; 30:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/39\">",
"      Lonstein JE, Winter RB. The Milwaukee brace for the treatment of adolescent idiopathic scoliosis. A review of one thousand and twenty patients. J Bone Joint Surg Am 1994; 76:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/40\">",
"      Fernandez-Feliberti R, Flynn J, Ramirez N, et al. Effectiveness of TLSO bracing in the conservative treatment of idiopathic scoliosis. J Pediatr Orthop 1995; 15:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/41\">",
"      Noonan KJ, Weinstein SL, Jacobson WC, Dolan LA. Use of the Milwaukee brace for progressive idiopathic scoliosis. J Bone Joint Surg Am 1996; 78:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/42\">",
"      Miller JA, Nachemson AL, Schultz AB. Effectiveness of braces in mild idiopathic scoliosis. Spine (Phila Pa 1976) 1984; 9:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/43\">",
"      Goldberg CJ, Dowling FE, Hall JE, Emans JB. A statistical comparison between natural history of idiopathic scoliosis and brace treatment in skeletally immature adolescent girls. Spine (Phila Pa 1976) 1993; 18:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/44\">",
"      Screening for adolescent idiopathic scoliosis. Review article. US Preventive Services Task Force. JAMA 1993; 269:2667.",
"     </a>",
"    </li>",
"    <li>",
"     Canadian Task Force on the Periodic Health Examination. In: Canadian Guide to Clinical Preventive Care, Canada Communication Group, Ottawa 1994. p.346.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/46\">",
"      School screening for scoliosis. Br Med J (Clin Res Ed) 1983; 287:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/47\">",
"      Green NE. Part-time bracing of adolescent idiopathic scoliosis. J Bone Joint Surg Am 1986; 68:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/48\">",
"      Rowe DE, Bernstein SM, Riddick MF, et al. A meta-analysis of the efficacy of non-operative treatments for idiopathic scoliosis. J Bone Joint Surg Am 1997; 79:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/49\">",
"      Danielsson AJ, Nachemson AL. Radiologic findings and curve progression 22 years after treatment for adolescent idiopathic scoliosis: comparison of brace and surgical treatment with matching control group of straight individuals. Spine (Phila Pa 1976) 2001; 26:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/50\">",
"      Lenssinck ML, Frijlink AC, Berger MY, et al. Effect of bracing and other conservative interventions in the treatment of idiopathic scoliosis in adolescents: a systematic review of clinical trials. Phys Ther 2005; 85:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/51\">",
"      Negrini S, Minozzi S, Bettany-Saltikov J, et al. Braces for idiopathic scoliosis in adolescents. Cochrane Database Syst Rev 2010; :CD006850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/52\">",
"      Kahanovitz N, Levine DB, Lardone J. The part-time Milwaukee brace treatment of juvenile idiopathic scoliosis. Long-term follow-up. Clin Orthop Relat Res 1982; :145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/53\">",
"      Price CT. A meta-analysis of the efficacy of non-operative treatments for idiopathic scoliosis. J Bone Joint Surg Am 1998; 80:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/54\">",
"      DiRaimondo CV, Green NE. Brace-wear compliance in patients with adolescent idiopathic scoliosis. J Pediatr Orthop 1988; 8:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/55\">",
"      Karol LA. Effectiveness of bracing in male patients with idiopathic scoliosis. Spine (Phila Pa 1976) 2001; 26:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/56\">",
"      O'Neill PJ, Karol LA, Shindle MK, et al. Decreased orthotic effectiveness in overweight patients with adolescent idiopathic scoliosis. J Bone Joint Surg Am 2005; 87:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/57\">",
"      Nicholson GP, Ferguson-Pell MW, Smith K, et al. The objective measurement of spinal orthosis use for the treatment of adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2003; 28:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/58\">",
"      Miller DJ, Franzone JM, Matsumoto H, et al. Electronic monitoring improves brace-wearing compliance in patients with adolescent idiopathic scoliosis: a randomized clinical trial. Spine (Phila Pa 1976) 2012; 37:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/59\">",
"      Kahanovitz N, Snow B, Pinter I. The comparative results of psychologic testing in scoliosis patients treated with electrical stimulation or bracing. Spine (Phila Pa 1976) 1984; 9:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/60\">",
"      F&auml;llstr&ouml;m K, Cochran T, Nachemson A. Long-term effects on personality development in patients with adolescent idiopathic scoliosis. Influence of type of treatment. Spine (Phila Pa 1976) 1986; 11:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/61\">",
"      Debeer P, Van Den Eede E, Moens P. Scapular winging: an unusual complication of bracing in idiopathic scoliosis. Clin Orthop Relat Res 2007; 461:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/62\">",
"      Sarwark JF. Idiopathic scoliosis: New instrumentation for surgical management. J Am Acad Orthop Surg 1994; 2:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/63\">",
"      Gitelman Y, Lenke LG, Bridwell KH, et al. Pulmonary function in adolescent idiopathic scoliosis relative to the surgical procedure: a 10-year follow-up analysis. Spine (Phila Pa 1976) 2011; 36:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/64\">",
"      Geck MJ, Rinella A, Hawthorne D, et al. Comparison of surgical treatment in Lenke 5C adolescent idiopathic scoliosis: anterior dual rod versus posterior pedicle fixation surgery: a comparison of two practices. Spine (Phila Pa 1976) 2009; 34:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/65\">",
"      Lonner BS, Auerbach JD, Estreicher M, et al. Video-assisted thoracoscopic spinal fusion compared with posterior spinal fusion with thoracic pedicle screws for thoracic adolescent idiopathic scoliosis. J Bone Joint Surg Am 2009; 91:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/66\">",
"      Fabry G. Allograft versus autograft bone in idiopathic scoliosis surgery: a multivariate statistical analysis. J Pediatr Orthop 1991; 11:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/67\">",
"      Niemeyer T, Freeman BJ, Grevitt MP, Webb JK. Anterior thoracoscopic surgery followed by posterior instrumentation and fusion in spinal deformity. Eur Spine J 2000; 9:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/68\">",
"      Hefti FL, McMaster MJ. The effect of the adolescent growth spurt on early posterior spinal fusion in infantile and juvenile idiopathic scoliosis. J Bone Joint Surg Br 1983; 65:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/69\">",
"      Sanders JO, Herring JA, Browne RH. Posterior arthrodesis and instrumentation in the immature (Risser-grade-0) spine in idiopathic scoliosis. J Bone Joint Surg Am 1995; 77:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/70\">",
"      Burton DC, Asher MA, Lai SM. Scoliosis correction maintenance in skeletally immature patients with idiopathic scoliosis. Is anterior fusion really necessary? Spine (Phila Pa 1976) 2000; 25:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/71\">",
"      Aurori BF, Weierman RJ, Lowell HA, et al. Pseudarthrosis after spinal fusion for scoliosis. A comparison of autogeneic and allogeneic bone grafts. Clin Orthop Relat Res 1985; :153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/72\">",
"      Stasikelis PJ, Pugh LI, Allen BL Jr. Surgical corrections in scoliosis: a meta-analysis. J Pediatr Orthop B 1998; 7:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/73\">",
"      Merola AA, Haher TR, Brkaric M, et al. A multicenter study of the outcomes of the surgical treatment of adolescent idiopathic scoliosis using the Scoliosis Research Society (SRS) outcome instrument. Spine (Phila Pa 1976) 2002; 27:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/74\">",
"      Diab M, Smith AR, Kuklo TR, Spinal Deformity Study Group. Neural complications in the surgical treatment of adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2007; 32:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/75\">",
"      Schwartz DM, Auerbach JD, Dormans JP, et al. Neurophysiological detection of impending spinal cord injury during scoliosis surgery. J Bone Joint Surg Am 2007; 89:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/76\">",
"      Johnston CE 2nd, Happel LT Jr, Norris R, et al. Delayed paraplegia complicating sublaminar segmental spinal instrumentation. J Bone Joint Surg Am 1986; 68:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/77\">",
"      Coe JD, Arlet V, Donaldson W, et al. Complications in spinal fusion for adolescent idiopathic scoliosis in the new millennium. A report of the Scoliosis Research Society Morbidity and Mortality Committee. Spine (Phila Pa 1976) 2006; 31:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/78\">",
"      Rubery PT, Bradford DS. Athletic activity after spine surgery in children and adolescents: results of a survey. Spine (Phila Pa 1976) 2002; 27:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/79\">",
"      Fabricant PD, Admoni S, Green DW, et al. Return to athletic activity after posterior spinal fusion for adolescent idiopathic scoliosis: analysis of independent predictors. J Pediatr Orthop 2012; 32:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/80\">",
"      Weinstein SL, Dolan LA, Spratt KF, et al. Health and function of patients with untreated idiopathic scoliosis: a 50-year natural history study. JAMA 2003; 289:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/81\">",
"      Weinstein SL. Idiopathic scoliosis. Natural history. Spine (Phila Pa 1976) 1986; 11:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/82\">",
"      Weinstein SL, Zavala DC, Ponseti IV. Idiopathic scoliosis: long-term follow-up and prognosis in untreated patients. J Bone Joint Surg Am 1981; 63:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/83\">",
"      Mayo NE, Goldberg MS, Poitras B, et al. The Ste-Justine Adolescent Idiopathic Scoliosis Cohort Study. Part III: Back pain. Spine (Phila Pa 1976) 1994; 19:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/84\">",
"      Dickson JH, Erwin WD, Rossi D. Harrington instrumentation and arthrodesis for idiopathic scoliosis. A twenty-one-year follow-up. J Bone Joint Surg Am 1990; 72:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/85\">",
"      Collis DK, Ponseti IV. Long-term follow-up of patients with idiopathic scoliosis not treated surgically. J Bone Joint Surg Am 1969; 51:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/86\">",
"      Andersen MO, Christensen SB, Thomsen K. Outcome at 10 years after treatment for adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2006; 31:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/87\">",
"      Haefeli M, Elfering A, Kilian R, et al. Nonoperative treatment for adolescent idiopathic scoliosis: a 10- to 60-year follow-up with special reference to health-related quality of life. Spine (Phila Pa 1976) 2006; 31:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/88\">",
"      Cordover AM, Betz RR, Clements DH, Bosacco SJ. Natural history of adolescent thoracolumbar and lumbar idiopathic scoliosis into adulthood. J Spinal Disord 1997; 10:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/89\">",
"      Goldberg MS, Mayo NE, Poitras B, et al. The Ste-Justine Adolescent Idiopathic Scoliosis Cohort Study. Part I: Description of the study. Spine (Phila Pa 1976) 1994; 19:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/90\">",
"      Asher MA, Burton DC. Adolescent idiopathic scoliosis: natural history and long term treatment effects. Scoliosis 2006; 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/91\">",
"      Nilsonne U, Lundgren KD. Long-term prognosis in idiopathic scoliosis. Acta Orthop Scand 1968; 39:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/92\">",
"      Payne WK 3rd, Ogilvie JW, Resnick MD, et al. Does scoliosis have a psychological impact and does gender make a difference? Spine (Phila Pa 1976) 1997; 22:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/93\">",
"      Akazawa T, Minami S, Kotani T, et al. Long-term clinical outcomes of surgery for adolescent idiopathic scoliosis 21 to 41 years later. Spine (Phila Pa 1976) 2012; 37:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/94\">",
"      Berman AT, Cohen DL, Schwentker EP. The effects of pregnancy on idiopathic scoliosis. A preliminary report on eight cases and a review of the literature. Spine (Phila Pa 1976) 1982; 7:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/95\">",
"      Blount WP, Mellencamp D. The effect of pregnancy on idiopathic scoliosis. J Bone Joint Surg Am 1980; 62:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/96\">",
"      Betz RR, Bunnell WP, Lambrecht-Mulier E, MacEwen GD. Scoliosis and pregnancy. J Bone Joint Surg Am 1987; 69:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/97\">",
"      Bunnell WP. The natural history of idiopathic scoliosis. Clin Orthop Relat Res 1988; :20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37065/abstract/98\">",
"      Visscher W, Lonstein JE, Hoffman DA, et al. Reproductive outcomes in scoliosis patients. Spine (Phila Pa 1976) 1988; 13:1096.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6291 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-217.16.9.173-E29AE5AA73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37065=[""].join("\n");
var outline_f36_12_37065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Referral indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OBSERVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BRACING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Efficacy of bracing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Duration of use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hours per day",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Efficacy of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pre-op evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Activity restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H449313343\">",
"      Metal detectors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Curve progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Back pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Psychosocial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6291\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6291|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/58/24494\" title=\"diagnostic image 1\">",
"      Thoracolumbar scoliosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/46/15087\" title=\"diagnostic image 2\">",
"      Cobb angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/24/32136\" title=\"diagnostic image 3\">",
"      Posterior spinal fusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6291|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/0/33806\" title=\"picture 1\">",
"      Use of the scoliometer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/7/35966\" title=\"picture 2\">",
"      Boston brace",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=related_link\">",
"      Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/20/18754?source=related_link\">",
"      Patient information: Scoliosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27832?source=related_link\">",
"      Red cell transfusion in infants and children: Selection of blood products",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_12_37066="Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease";
var content_f36_12_37066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37066/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37066/contributors\">",
"     Charles H Hennekens, MD, DrPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37066/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37066/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37066/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/12/37066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/12/37066/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/12/37066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease (CVD), which includes coronary heart disease (CHD), cerebrovascular disease, and peripheral artery disease, is far and away the leading the cause of death in most developed countries, accounting for more than 900,000 deaths annually in the United States alone. The totality of evidence from basic research, clinical investigations, observational epidemiologic studies, and randomized clinical trials has provided strong support for the net benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in decreasing the risk of CVD events in a wide range of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In secondary prevention of CVD after acute myocardial infarction (MI), occlusive stroke, transient ischemic attack (TIA), stable angina, and coronary artery bypass surgery to reduce risks of MI, stroke and vascular death.",
"     </li>",
"     <li>",
"      In acute ischemic syndromes such as acute MI and unstable angina (UA) and long term to reduce risks of recurrent MI, stroke, and vascular death.",
"     </li>",
"     <li>",
"      In acute occlusive stroke and long term to reduce risks of MI, recurrent stroke, and vascular death.",
"     </li>",
"     <li>",
"      In primary prevention of a first cardiovascular event as an individual clinical judgment for apparently health men and women at moderate to high risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence supporting the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for a wide range of patients at high or moderate risk of CVD, including optimal dosing, and the relative and absolute risks of side effects will be reviewed here. The use of aspirin in primary prevention of CVD as well as cancer is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=see_link\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several randomized trials as well as their meta-analyses have established the statistically significant and clinically important net benefits of the early initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with acute coronary syndromes. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    as adjunctive therapy after percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG), and as secondary prevention after stroke or during the treatment of acute ischemic stroke are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link&amp;anchor=H3#H3\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets, platelet products, and clotting factors all play important and proximate causal roles in the occurrence of virtually all occlusive vascular events including MI as well as ischemic stroke. The disruption of platelet- and fibrin-rich atherosclerotic plaques may lead to enhanced platelet deposition, and ultimately the formation of a thrombus that can precipitate an acute clinical cardiovascular event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=see_link\">",
"     \"Platelet biology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4167?source=see_link\">",
"     \"The role of platelets in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to its well documented and clinically important antiplatelet effects,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , has been postulated to have other biologic mechanisms that may play a role in decreasing risks of CVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/3\">",
"     3",
"    </a>",
"    ]. One such mechanism may be via increased nitric oxide formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/4\">",
"     4",
"    </a>",
"    ], and another may be a positive effect on elevated levels of certain inflammatory markers, including proinflammatory cytokines and C-reactive protein (CRP). The relationship between CRP and aspirin use is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASPIRIN NONRESPONSE AND RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    resistance\" has been used to describe the occurrence of cardiovascular events despite regular aspirin intake at recommended doses. Such treatment failures resemble those with other drugs, including statins, beta blockers, and angiotensin converting enzyme inhibitors, all of which are of proven benefit in the treatment of CVD. When used for secondary prevention, all of these drugs reduce nonfatal CVD by about one-fourth and fatal events by about one-sixth. Thus, three-fourths of nonfatal and five-sixths of fatal events are not prevented by all these drugs, but these circumstances do not necessarily imply the presence of \"resistance\".",
"   </p>",
"   <p>",
"    The current lack of cogent evidence to support the clinical relevance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    \"resistance\" in the CVD events that continue to occur is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASPIRIN SENSITIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients are unable to tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    because of hypersensitivity, which is most often manifested clinically as respiratory tract disease (rhinitis and asthma, 10 percent, rarely with systemic symptoms) or",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    (0.07 to 0.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. With some forms of aspirin sensitivity, cross-reactions occur with other NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clear benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in reducing risks of CVD raises clinical challenges for high-risk patients who require aspirin and have such sensitivities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with stable coronary disease,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      desensitization can be attempted, although this technique may not be effective in patients with underlying chronic urticaria. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26006?source=see_link\">",
"       \"Diagnostic challenge and desensitization protocols for NSAID reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with an acute coronary syndrome or for those who cannot undergo",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      desensitization,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      may be an effective alternative. Depending upon the clinical presentation and the need for percutaneous coronary intervention, other antithrombotic therapy may be added or substituted. Randomized data are lacking on the optimal strategy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BLEEDING RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main adverse effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is an increased risk of bleeding, chiefly from the gastrointestinal (GI) tract but also very rarely from intracranial vessels. Meta-analyses of randomized trials have demonstrated that five years of treatment with 325 mg aspirin daily produces a nearly one percent absolute increase in risk of GI bleeding compared to placebo (2.47 versus 1.42 percent with placebo at an average of 28 months and 1.3 versus 0.5 percent at variable follow-up) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. A nonsignificant increase in the risk of hemorrhagic stroke of about one-third has been observed in the meta-analyses of the primary prevention trials. This relative increase corresponds to a very small absolute annual increase of around 2 hemorrhagic strokes per 10,000 allocated to aspirin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link&amp;anchor=H8#H8\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of major bleeding, as well as occlusive vascular events, are likely to be higher in the general population than among willing and eligible participants in randomized trials. In a population-based study, 186,425 Italian citizens with a new prescription for low-dose (&le;300 mg)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    were compared with an equal number not prescribed aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/11\">",
"     11",
"    </a>",
"    ]. The primary outcome was hospitalization for major GI bleeding and or cerebral hemorrhage. After a median follow-up of 5.7 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those who self-selected for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use had a higher overall incidence of hemorrhagic events (5.58 versus 3.60 per 1000 person-years; incidence rate ratio 1.55, 95% CI 1.48-1.63). Aspirin use was associated with an increase in 20 major bleeding events for every 10,000 treated patients. The incidence rate ratios were similar for the relatively common gastrointestinal bleeds and the rare intracranial bleeds.",
"     </li>",
"     <li>",
"      In subgroup analyses of patients with diabetes, self selection for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use was not associated with a significant increase in hemorrhagic events (incidence risk ratio 1.09, 95% CI 0.97-1.22). (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Impact of diabetes'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      When",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is used for (across a broad population of patients at differing risks), the increase in the risk of major bleeding appears comparable to the reduction in the risk of cardiovascular events. The issue is discussed in detail below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dosing and bleeding risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In indirect comparisons in the worldwide meta-analysis conducted by the Antithrombotic Trialists' Collaboration, there were no significant differences between 75 and 325 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and risks of major extracranial bleeding based on data from three individual randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In nonrandomized post hoc subgroup analyses from the CURE and BRAVO trials, which are useful to formulate but not test hypotheses, there was an increase in bleeding risk at higher doses within the low-dose range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/13,14\">",
"     13,14",
"    </a>",
"    ] but confounding by indication was a plausible alternative explanation",
"   </p>",
"   <p>",
"    In a 2006 systematic review of 22 randomized trials of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for adverse effects, the following findings were noted for aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      increased the risk of any major bleeding, major GI bleeding, and intracranial bleeding 1.7 to 2.1 times compared to placebo. The absolute annual increase in risk was 1.3 per 1000 patients for all major bleeding episodes (mostly GI) and 3 per 10,000 for intracranial bleeding.",
"     </li>",
"     <li>",
"      There was no difference in bleeding risk at",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      doses of &gt;162 to 325",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      compared to 75 to 162",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a nonrandomized, post hoc subgroup analysis from the CHARISMA trial of patients with either established cardiovascular disease (about 12,000) or at high risk (about 4000) who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    75 mg daily or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/16\">",
"     16",
"    </a>",
"    ], all were given concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in a daily dose at the discretion of the investigators. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link&amp;anchor=H36#H36\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of severe or life-threatening bleeding (primary safety end point) was evaluated at a median of 28 months in relation to the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (&lt;100 mg, 100 mg, or &gt;100 mg daily) and whether or not the patient received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . There were no significant differences between the different aspirin dose groups in the adjusted hazard ratio for the incidence of severe or life-threatening bleeding. In addition, there was no effect modification by clopidogrel. &nbsp;",
"   </p>",
"   <p>",
"    In a 2011 meta-analysis, low doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone decreased the risk for all-cause mortality, increased the risk for GI bleeding which further increased with accompanying use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and anticoagulant therapies, but decreased in patients who took PPIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -associated gastrointestinal bleeding have been identified and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States Preventative Services Task Force (USPSTF) report on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the primary prevention of cardiovascular disease (CVD), the magnitude of increase in risk was estimated to be approximately two to three times higher in patients with a history of GI ulcer, and twice as high for men as women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link&amp;anchor=H5#H5\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Low dose aspirin for cardiovascular protection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Primary prevention of aspirin induced GI bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to the primary prevention of gastrointestinal toxicity from nonsteroidal antiinflammatory drugs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link&amp;anchor=H10#H10\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Prevention strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , such as those with acute coronary syndromes or placement of an intracoronary stent, are also on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . Reports in 2008 have raised the possibility that PPIs can interfere with clopidogrel's ability to impair platelet function. This issue and our recommendations for PPI use in patients taking long-term dual antiplatelet therapy with aspirin and clopidogrel are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=see_link&amp;anchor=H5971641#H5971641\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=see_link&amp;anchor=H32#H32\">",
"     \"Nonresponse and resistance to clopidogrel\", section on 'Proton pump inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Secondary prevention of GI bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk associated with restarting antiplatelet therapy in patients who have had an ulcer complication, mostly GI bleeding, has been evaluated in two randomized trials in which patients were first treated for eradication of Helicobacter pylori and therapy was restarted only if eradication of H. pylori and healing of the ulcer were documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/58/12197?source=see_link&amp;anchor=H4#H4\">",
"     \"NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity\", section on 'With continued low-dose aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, the following risks of recurrent bleeding were noted at one year; mean patient age was 70 to 72 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restarting low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      &mdash; 14.8 percent",
"     </li>",
"     <li>",
"      Substituting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      &mdash; 8.6 percent",
"     </li>",
"     <li>",
"      Restarting low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (80 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      with a proton pump inhibitor (PPI) &mdash; 0.7 to 1.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not surprisingly, a PPI did not protect against lower GI bleeding (4.6 percent at one year in both groups) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/20\">",
"     20",
"    </a>",
"    ]. The efficacy of adding a PPI in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    was not evaluated.",
"   </p>",
"   <p>",
"    The high bleeding risk with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    was a surprise since the ulcer risk with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other nonsteroidal antiinflammatory drugs is thought to be mediated primarily by inhibition of cyclooxygenase, which is not affected by clopidogrel. A possible mechanism is impaired healing of spontaneous asymptomatic ulcers that form at a rate of up to 2 percent per month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, further research is needed to determine the optimal regimen among patients who have had a gastrointestinal bleed on low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Based upon the currently available evidence, aspirin may be given with a PPI if the estimated cardiovascular risk of the patient warrants continued therapy. In a meta-analysis of six secondary prevention trials, it was estimated that 1.5 deaths could be prevented for every episode of nonfatal GI bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/58/12197?source=see_link&amp;anchor=H4#H4\">",
"     \"NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity\", section on 'With continued low-dose aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NONASPIRIN NSAIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One concern with the concurrent administration of nonsteroidal antiinflammatory drugs (NSAIDs) is a possible reduction of the cardioprotective effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Based upon the limited evidence available,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    and probably other nonselective NSAIDs may have a deleterious interaction with aspirin that may have clinical relevance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. It is possible that this deleterious interaction, if real, is mitigated by administering aspirin at least two hours before the NSAID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These issues as well as the effect of NSAID therapy (both nonselective and COX-2 selective) on cardiovascular risk in patients not taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SECONDARY PREVENTION OF CVD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    produces statistically significant and clinically important reductions in the risk of subsequent myocardial infarction (MI), stroke, and vascular death among a wide range of patients who have survived an occlusive cardiovascular disease event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/12,24\">",
"     12,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The conclusive benefits of long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy were best demonstrated in the Antithrombotic Trialists' Collaboration overview, which analyzed the results of 195 randomized trials of antiplatelet therapy, principally with aspirin, among more than 135,000 high-risk patients with prior evidence of CVD, including prior or acute MI, prior or acute stroke or transient ischemia attacks (TIA), and other high-risk groups such as unstable angina, stable angina, peripheral artery disease, CABG, PCI, atrial fibrillation, and valvular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major firm conclusions were as follows (",
"    <a class=\"graphic graphic_table graphicRef56243 \" href=\"mobipreview.htm?42/34/43564\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiplatelet therapy, primarily with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , significantly reduced the relative risk of subsequent vascular events (nonfatal MI, nonfatal stroke, and vascular death) by approximately 22 percent.",
"     </li>",
"     <li>",
"      In absolute terms, antiplatelet therapy led to avoidance of approximately 36 vascular events per 1000 patients with a prior MI treated for a mean of 27 months; 38 events per 1000 patients with an acute MI treated for one month; 36 events per 1000 patients with a previous stroke or TIA treated for 29 months; and 9 events per 1000 patients with an acute stroke treated for 0.7 months, and 22 events per 1000 patients with other high-risk features treated for 22 months.",
"     </li>",
"     <li>",
"      There was no difference in efficacy between doses of 75 to 150",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (called low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ) and 160 to 325",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (called medium-dose aspirin).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Use in heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with heart failure with or without vascular disease (including coronary disease) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42039?source=see_link&amp;anchor=H6#H6\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Comparison to thienopyridines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials of secondary prevention did not test whether thienopyridines added to the clinical benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , but instead compared aspirin with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The CAPRIE trial, for example, found that clopidogrel had a modest, and marginally significant advantage over aspirin for the prevention of stroke, MI, and vascular disease in 19,185 patients with a recent stroke, MI, or peripheral artery disease (annual event rate 5.3 versus 5.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A significant reduction in serious cardiovascular events was also noted with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the Antithrombotic Trialists' Collaboration report (10.1 versus 11.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/12\">",
"     12",
"    </a>",
"    ] and with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    or clopidogrel compared to aspirin in a meta-analysis of four trials with 22,656 patients at high risk for vascular disease (12 versus 13 percent at approximately two years, odds ratio 0.91) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the latter report,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    were associated with a lower incidence of gastrointestinal hemorrhage and upper-gastrointestinal upset, but a higher incidence of rash, diarrhea, and, with ticlopidine, neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/29\">",
"     29",
"    </a>",
"    ]. Clopidogrel is preferred to ticlopidine because it is safer. Any minimal improvement in efficacy with clopidogrel or ticlopidine compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    must be weighed against their much higher costs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cessation of aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    are acute and the half-life of a platelet is about eight days. Thus, cessation of aspirin may be associated with an increase in risk of complications such as MI, stroke, or stent thrombosis. The major reasons for physician-directed cessation of aspirin therapy in descriptions of complications have been minor surgery, endoscopy, and dental treatment. However, with respect to surgery, there is increasing evidence that aspirin should be continued in patients at high risk for perioperative occlusive vascular complications (eg, those undergoing coronary artery bypass graft or peripheral arterial surgery). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link&amp;anchor=H26#H26\">",
"     \"Perioperative medication management\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Concomitant use of ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors are standard therapy in patients with heart failure as well as most with prior myocardial infarction or diabetic patients not at goal blood pressure. Post hoc subgroup analyses of completed randomized trials had erroneously raised the possibility that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    might partially attenuate the benefit from ACE inhibitors. However, the totality of the evidence supports no deleterious interaction between ACE inhibitors and aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review of the effects of long-term treatment with ACE inhibitors in the presence or absence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    was performed on data from six major trials of 22,060 patients with cardiovascular disease (eg, heart failure, left ventricular dysfunction, or myocardial infarction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/32\">",
"     32",
"    </a>",
"    ]. The overall benefits of ACE inhibitors on major cardiovascular outcomes (eg, death, stroke, and all major vascular events) were greater in patients who also were given aspirin except for the data-dependent subgroup of myocardial infarction. This finding may be due to chance related to the large number of comparisons.",
"   </p>",
"   <p>",
"    In the absence of a contraindication,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and ACE inhibitors can be used safely in patients at high risk for major vascular events. As described in the next section, it may be prudent to use a maintenance aspirin dose of 75 to 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in such patients; low dose aspirin appears to provide the same cardiovascular benefit as higher doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1980s, the United States Food and Drug Administration (FDA) approved professional labeling indications for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with prior MI or unstable angina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/33\">",
"     33",
"    </a>",
"    ] and for men with prior transient ischemic attacks (TIAs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/34\">",
"     34",
"    </a>",
"    ]. In January 1997, at a joint meeting of the FDA's Nonprescription Drugs and Cardiovascular and Renal Drugs Advisory Committees, expansion of the professional labeling indication was recommended to include women as well as men with prior TIAs, prior occlusive stroke or chronic stable angina, and those who have undergone arterial revascularization procedures (either coronary artery bypass graft or percutaneous coronary intervention).",
"   </p>",
"   <p>",
"    The 2012 American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis guideline on the Primary and secondary prevention of cardiovascular disease makes a strong recommendation for either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for patients with established coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dosing and cardiovascular benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely tested regimen in the secondary prevention trials in the Antithrombotic Trialists' Collaboration was",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    at a dose of 75 to 325",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indirect and nonrandomized comparisons, including a post hoc subset analysis from the large CHARISMA trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/16\">",
"     16",
"    </a>",
"    ], showed no difference in efficacy between doses of 75 to 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (called low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) and 160 to 325",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (called medium-dose aspirin), as the proportional reduction in events was 32 and 26 percent, respectively, or higher doses up to 1500",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    In such comparisons, there is confounding by indication as most patients assigned to higher doses entered with cerebrovascular disease and most assigned to low doses had prior cardiac events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/3,12,36,37\">",
"     3,12,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    doses below 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    might be more effective than higher doses because such low doses are reported to \"spare\" prostacyclin (a platelet antiaggregant and vasodilator) and cause less bleeding. With respect to efficacy, based on small numbers of events in only three randomized trials, doses below 75 mg daily showed a nonsignificant benefit of about 13 percent, which was about one-half the significant overall benefit of about 25 percent seen with higher doses up to 1500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, the United States Food and Drug Administration recommends daily doses of 75 to 325 mg, while the 2006 American College of Cardiology",
"    <span class=\"nowrap\">",
"     /American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on secondary prevention recommends daily doses of 75 to 162 mg for secondary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/38\">",
"     38",
"    </a>",
"    ]. The ACCP recommends a daily dose of 75 to 100 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe the totality of evidence suggests that doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    from 75 to 325 mg daily are associated with the best",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio. Some experts prefer to stay within the 75 to 162 mg per day range.",
"   </p>",
"   <p>",
"    In patients with acute occlusive events, a loading dose of at least 162 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and preferably 325 mg should be given to achieve a rapid clinical antithrombotic effect. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Aspirin formulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    &mdash; regular, buffered, or enteric coated &mdash; should be an individual clinical decision made with the patient. Enteric coated aspirin is designed to resist disintegration in the stomach; thus, health care providers and their patients may believe this to be an attractive alternative to conventional aspirin. Although this preparation may reduce erosions on endoscopy, enteric coating does not appear to protect against the clinically relevant end point of gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/39\">",
"     39",
"    </a>",
"    ]. This finding is not surprising, since injury severe enough to induce bleeding is thought to reflect the systemic rather than just the local effects of aspirin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link&amp;anchor=H4#H4\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Enteric-coated and buffered aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\", section on 'Systemic versus topical effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/40\">",
"     40",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] studies, equivalent doses of enteric coated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    are not as effective as plain aspirin. Lower bio-availability of these preparations and poor absorption from the higher pH environment of the small intestine may result in inadequate platelet inhibition, particularly in heavier subjects. These data contribute to the formulation of the hypothesis that low dose enteric coated aspirin does not produce adequate platelet inhibition.",
"   </p>",
"   <p>",
"    In acute occlusive vascular events (eg, acute coronary syndrome), the necessity to achieve a rapid clinical antithrombotic effect precludes the recommendation of enteric coated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    because of its delayed absorption. If the only available preparation is enteric coated, the single tablet or multiple tablets necessary to achieve the recommended dose of 325mg should be crushed or chewed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PRIMARY PREVENTION OF CVD",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section presents an in-depth review of the evidence on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the primary prevention of cardiovascular events. The evidence on aspirin in the primary prevention of cancer is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=see_link\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on evidence from nine large-scale primary prevention trials of men and women without established cardiovascular disease (CVD),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    produces a statistically significant and clinically important reduction in the risk of a first MI. However, aspirin has not been shown to lead to a statistically significant reduction in the rates of stroke or cardiovascular death.",
"   </p>",
"   <p>",
"    We believe that any decision to prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for primary prevention of cardiovascular disease should be an individual clinical judgment that weighs the absolute benefit in reducing the risk of a first MI against the absolute risk of major bleeding with long-term administration. The higher the risk of cardiovascular events the greater the likely benefit from aspirin. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Estimating the benefit to risk ratio'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive 2009 meta analysis of six trials that included individual patient level data among over 95,000 men and women who were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (at dose between 75 and 500 mg per day) or placebo showed the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      significantly reduced the incidence of serious vascular events, defined as a prespecified combined endpoint of myocardial infarction (MI), death from a vascular cause (including sudden death, pulmonary embolism, hemorrhage), or stroke (0.51 versus 0.57 percent per year). This significant reduction was attributable principally to a significant reduction in first non-fatal MI (0.18 versus 0.23 percent per year).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      significantly increased the rate of major gastrointestinal and extracranial bleeds (0.10 versus 0.07 percent per year).",
"     </li>",
"     <li>",
"      The proportional reductions were similar for women and men.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three meta-analyses, published in 2011 and 2012 added approximately 6000 additional patients from three trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/44-46\">",
"     44-46",
"    </a>",
"    ] to the comprehensive meta analysis of over 95,000 patients published in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Not surprisingly, these meta-analyses came to similar conclusions to the 2009 study. In the 2012 meta-analysis, net cardiovascular benefit exceeded the bleeding risk at higher baseline cardiovascular disease events rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Individual trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are the nine randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    to placebo that are included in the above meta-analyses. Nearly 80 percent of patients who received aspirin came from the Physician&rsquo;s Health Study, the Women&rsquo;s Health Study, and the Hypertension Optimal Treatment Trial so the 10-year risk of a first event in these patients is far lower than the 10 percent, which indicates moderate risk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physician&rsquo;s Health Study &ndash; The United States Physician's Health Study (PHS) was the first to demonstrate that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      reduces the risk of a first MI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/50\">",
"       50",
"      </a>",
"      ]. Aspirin was given at a dose of 325 mg daily every other day.",
"     </li>",
"     <li>",
"      British Doctor&rsquo;s Trial &ndash; In the British Doctor's Trial (BDT),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was given at a dose of 500 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thrombosis Prevention Trial - The relative benefit of low-dose (75 mg)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy (international normalized ratio goal of 1.5) in patients at high risk was addressed in the Thrombosis Prevention Trial (TPT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/52\">",
"       52",
"      </a>",
"      ]. This trial used a 2-by-2 factorial design to evaluate low-dose aspirin (75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      warfarin (target INR 1.5).",
"     </li>",
"     <li>",
"      Hypertension Optimal Treatment Trial &ndash; In the Hypertension Optimal Treatment (HOT) Trial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was given at a dose of 75 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primary Prevention Project &ndash; In the Primary Prevention Project (PPP), enteric-coated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was given at a dose of 100 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women&rsquo;s Health Study &ndash; In the Women's Health Study (WHS),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was given at a dose of 100 mg on alternate days for a mean of 10.1 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      for Asymptomatic Atherosclerosis trial &ndash; In the Aspirin for Asymptomatic Atherosclerosis trial (AAAT), aspirin was given at a dose of 100 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      JPAD trial &ndash; In the Japanese Primary Prevention of Atherosclerosis With",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      for Diabetes (JPAD) trial, aspirin was given at a dose of 81 to 100 mg daily to patients with diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      POPADAD trial &ndash; In the Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was given at a dose of 100 mg daily to patients with diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Estimating the benefit to risk ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual clinical decision making for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the primary prevention of CVD is far more complex than that for secondary prevention. In secondary prevention, the randomized evidence has far more stroke and CVD death endpoints and shows conclusive benefits on MI, stroke, and CVD death. When aspirin is used for secondary prevention, the benefit of therapy (at least a 20 percent relative risk reduction in a population whose 10-year risk is greater than 20 percent) almost always exceeds the absolute risk (ranging from about 1 percent in young to about 4 percent in older individuals) of major extracranial bleeding as well as the very serious but very rare risk of hemorrhagic stroke.",
"   </p>",
"   <p>",
"    In primary prevention, the randomized evidence shows conclusive benefits on first MI, but the data on stroke and CVD death remain inconclusive. In addition, the absolute risk reduction is far lower for primary prevention; in the primary prevention trials the average absolute risk was less than 5 percent (a 20 percent relative risk reduction in a patient with a 10-year risk of 5 percent is about 1 percent; a 10 percent relative risk reduction in a patient with a 10-year risk of 5 percent is about 0.5 percent). Further, if one assumes that the risk of a bleeding event is the same as described for secondary prevention the benefits outweigh the risks only when the risk of a cardiovascular event begins to exceed 6 to 10 percent in ten years (",
"    <a class=\"graphic graphic_table graphicRef53748 \" href=\"mobipreview.htm?1/62/2030\">",
"     table 2C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, however, age is a risk factor for bleeding as well as occlusion. Further, not all patients are at equal risk for the development of major bleeding. Patients with a history of GI bleed, those on chronic nonsteroidal antiinflammatory therapy, and those with GI symptoms attributable to or history of ulcer disease, gastritis, or gastroesophageal reflux disease are at increased risk.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Bleeding risk'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest assessing the net benefit (reduction in CHD events minus an increase in the risk of major bleeding) of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    using the following guidelines from the USPSTF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The individual patient's risk of a first cardiovascular event should be calculated. We suggest using a calculator that uses a multivariable risk function derived from data in the Framingham Heart Study&nbsp;(",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/28/44482?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/63/10226?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"       \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The magnitude of the benefit and risk can be estimated from existing tables provided by the USPSTF (",
"      <a class=\"graphic graphic_table graphicRef72074 graphicRef62463 graphicRef53748 \" href=\"mobipreview.htm?30/49/31519\">",
"       table 2A-C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      should be prescribed based on an individual clinical judgment when the magnitude of the absolute benefit exceeds the magnitude of the absolute harm (",
"      <a class=\"graphic graphic_table graphicRef53748 \" href=\"mobipreview.htm?1/62/2030\">",
"       table 2C",
"      </a>",
"      ). When the magnitude of benefit is similar to that of risk, patient preference may be considered [USPSTF]. For instance, an individual who feels that the prevention of an MI or stroke is more important than the development of a gastrointestinal bleed may state a clear preference for aspirin use.",
"     </li>",
"     <li>",
"      This general approach may not be useful in patients with risk factors for bleeding such as history of GI bleeding or ulcers, nonsteroidal antiinflammatory drug use, or upper gastrointestinal tract pain, as their risk of GI bleeding is much higher. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients are at particularly high risk, such as those over age 40 with metabolic syndrome whose 10-year risks of a first CHD event are 16 to 18 percent. As such, it may be prudent to consider",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    as an adjunct to statins for primary prevention. The decision, however, should be an individual clinical judgement that weighs the magnitude of the absolute benefit on first MI against the magnitude of the absolute risk, chiefly major bleeding. We believe that any general guidelines for aspirin in primary prevention should include the results of ongoing randomized trials of aspirin in moderate- to high-risk primary prevention subjects. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Impact of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The six large scale randomized trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in primary prevention include over 90,000 subjects from age 40 to 89, but their average 10-year risk of a first CHD event is less than 5 percent. Further randomized evidence is accumulating in several large scale randomized trials, in particular ARRIVE and ASPREE which target patients at moderate to high risk with an average risk of a first CHD event of 10 to 19 percent. Since risk of a first CHD event increases with age in men and women, these trials will include a greater preponderance of older subjects. Such data should form a rational basis for guidelines for primary prevention in moderate to high-risk men and women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Impact of gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The totality of randomized evidence suggests no differences in response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    between men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/56\">",
"     56",
"    </a>",
"    ]. A 2009 meta-analysis of the results from 22 trials of primary and secondary prevention, included about 135,000 patients, and showed no difference in the response to aspirin between men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/43\">",
"     43",
"    </a>",
"    ]. A 2002 meta-analysis of the trials of secondary prevention came to a similar conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the WHS",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    showed a significant benefit on risk of a first stroke but not a first MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/55\">",
"     55",
"    </a>",
"    ]. Since 90 percent of the subjects were under 65 the predominant occlusive vascular event in such women is stroke, not MI. In the 10 percent of women aged 65 and over who accrued 30 percent of the endpoints, MI was far more common and aspirin reduced the risk of a first MI to the same degree as in the previous trials of primary prevention predominantly in men.",
"   </p>",
"   <p>",
"    This hypothesis of possible gender differences had been formulated from a 2006 gender specific meta-analysis of randomized trials restricted to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the primary prevention of cardiovascular disease suggested a gender difference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/57\">",
"     57",
"    </a>",
"    ]. In this meta-analysis of over 51,000 women, about 80 percent of women were from the Women&rsquo;s Health Study (WHS) discussed above. Aspirin was associated with a significant 12 percent reduction in the combined cardiovascular outcome of nonfatal MI, nonfatal stroke, and cardiovascular mortality (odds ratio 0.88; 95% CI 0.79-0.99), attributable principally to a significant 33 percent MI reduction in men and 17 percent stroke reduction in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Impact of diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the most recent (2002) version of the National Cholesterol Education Program Adult Treatment Panel III, diabetes was elevated from a major risk factor to a coronary heart disease (CHD) risk equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/58\">",
"     58",
"    </a>",
"    ]. The rationale for this change derives, in part, from earlier observations that patients with diabetes have several-fold increased risks of CHD, which are even greater in women than men. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H4873275#H4873275\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the primary prevention of CVD among patients with diabetes, but no other risk factors, evidence of benefit is conflicting. Further randomized evidence is necessary and will emerge over the next several years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on the available evidence, a 2010 expert consensus document written jointly by the American Diabetes Association, American Heart Association, and the American College of Cardiology Foundation made the following recommendations for the use of low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75-162 mg daily) in adults with diabetes but no history of cardiovascular disease (CVD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      may be considered for those whose 10 year risk of CVD events is greater than or equal to 10 percent and in whom the risk of bleeding is not increased.",
"     </li>",
"     <li>",
"      A weaker recommendation, based on weak evidence, was made for patients whose 10 year risk of CVD events is between 5 and 10 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations do not differ in substance from our recommendations for primary prevention. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The viewpoint of this consensus document, as well as the 2012 American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis guideline on the Primary and secondary prevention of cardiovascular disease, is that diabetes should be considered a risk factor, as opposed to a CHD equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2012 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice make a strong recommendation to not prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for patients with diabetes if cardiovascular disease is not present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80547560\">",
"    <span class=\"h2\">",
"     Possible benefit for the prevention of cancer related events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for primary prevention of CVD as well as cancer is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=see_link\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 United States Preventive Services Task Force (USPTF) statement on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the prevention of cardiovascular disease makes strong but separate recommendations for women and men, based on their interpretation of the above trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/18,62\">",
"     18,62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women aged 55 to 79 years when the potential benefit of a reduction in ischemic stroke outweighs the risk of an increase in gastrointestinal hemorrhage.",
"     </li>",
"     <li>",
"      In men aged 45 to 79 when the potential benefit from a reduction in the rate of myocardial infarction outweighs the risk of an increase in gastrointestinal hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2012 American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis guideline on the Primary and secondary prevention of cardiovascular disease makes a weak recommendation for low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (as opposed to no aspirin) for primary prevention in all persons over the age of 50 years. The document acknowledges the importance of individual clinical judgement, which should include an assessment of the absolute benefits and risks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H438151489\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach summarized below takes into account only the prevention of cardiovascular disease events. As mentioned at the beginning of the section, we believe that the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should take into account the primary prevention of both cardiovascular disease and cancer. This approach is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=see_link\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in primary prevention of cardiovascular disease have far more uncertainties than for secondary prevention. We believe that healthcare providers should make individual clinical judgments about the use of aspirin for primary prevention in those apparently healthy men and women whose absolute benefit on reducing cardiovascular events will outweigh their risks of major bleeding. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Primary prevention of CVD'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    At present, judgments about prescribing long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy for apparently healthy individuals at intermediate cardiovascular risk should continue to be made on a case-by-case basis. Such decisions should be based on individual clinical judgments between the healthcare provider and each of his or her patients. The decision should involve the absolute risk of an important vascular event as well as the absolute risk of a major extracranial bleed. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Efficacy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H32\">",
"     'Estimating the benefit to risk ratio'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following points may be considered decision making:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For low-risk patients (ie, men and women whose 10-year risk of a first coronary heart disease event is less than 10 percent), the absolute benefit on occlusive vascular events may be less than the absolute risk of major bleeding. &nbsp;",
"     </li>",
"     <li>",
"      For moderate risk patients (ie, men and women whose 10-year absolute risk of a first CHD event is 10 to 19 percent), the randomized data on benefits and risks are sparse, so clinical decision making should be made on an individual basis for those men and women in whom the benefits of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      to prevent a first myocardial infarction are likely to exceed their risk of major extra-cranial bleeding. In these patients, it should also be noted that aggressive risk-preventative strategies, including the use of statins, will reduce both myocardial infarction and occlusive stroke with little hazard. An informed clinical decision should include whether to use aspirin as an adjunct, not alternative to other therapeutic lifestyle changes and pharmacologic measures.",
"     </li>",
"     <li>",
"      We believe that individual clinical judgement should be considered for those subjects whose 10-year risk of a first event is 10 percent or greater while awaiting the results of the ongoing randomized trials directly testing this hypothesis. &nbsp;",
"     </li>",
"     <li>",
"      Available data suggest that daily doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      between 75 and 325 mg are equally safe and effective. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Primary prevention of CVD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     UNDERUTILIZATION OF ASPIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the established benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with a wide range of prior occlusive vascular diseases, its use remains suboptimal. In addition, aspirin remains an underutilized treatment for acute MI. In a national registry of more than 1000 larger United States hospitals, only 77 percent of acute MI patients received aspirin in 1993 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/63\">",
"     63",
"    </a>",
"    ]. Similar findings were noted in a 1992 to 1993 study of patients 65 years of age and older: only 61 percent were receiving aspirin within two days of hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/64\">",
"     64",
"    </a>",
"    ]. Increasing the use of aspirin to virtually all acute MI patients would save an additional 5000 to 10,000 lives in the United States each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    utilization in patients with an acute MI in the United States appears to be improving over time. This was illustrated in a report in which a cohort of Medicare patients hospitalized with acute MI (both STEMI and NSTEMI) between 1994 and 1995 (over 230,000 patients) was compared with a cohort hospitalized between 1998 and 1999 (over 35,000 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/66\">",
"     66",
"    </a>",
"    ]. The use of several recommended therapies increased over time, including early aspirin (76 to 83 percent) and aspirin at discharge (77 to 83 percent).",
"   </p>",
"   <p>",
"    While 60 to 84 percent of patients in the United States hospitalized for unstable angina or an MI receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , it is less frequently used in outpatients with coronary artery disease or diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. One study of 10,942 visits to cardiologists or primary care physicians by patients with coronary disease found that, for the period of 1993 to 1996, aspirin use was 26 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/68\">",
"     68",
"    </a>",
"    ]. Aspirin use was more frequently reported by cardiologists than internists, family practitioners, or general practitioners (37 versus 20, 18, and 11 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611366894\">",
"    <span class=\"h1\">",
"     ANTICOAGULATED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the evidence presented above, which shows that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    reduces the rate of adverse cardiovascular events in most patients with established disease and many at high risk, the addition of aspirin (or other antiplatelet agent) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in patients with an indication for the latter has not been shown to improve outcomes. This section will outline the rationale for not recommending aspirin for anticoagulated patients who would otherwise seem to benefit.",
"   </p>",
"   <p>",
"    Patients who potentially could benefit from both antiplatelet and anticoagulant therapy are common. For example, it is estimated that between 5 and 10 percent of patients scheduled for percutaneous coronary intervention (PCI) are taking oral anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=see_link&amp;anchor=H1#H1\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with cardiovascular disease who must be anticoagulated, it is important to know whether the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    significantly improves outcomes (reduction in the risk of adverse ischemic cardiovascular events) since the risk of major bleeding increases significantly when both agents are used compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=see_link&amp;anchor=H8#H8\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'Rates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first step in supporting a recommendation to not add",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is to demonstrate that anticoagulant therapy lowers the rate of ischemic heart disease events in patients not taking aspirin. The following two studies are relevant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2003 meta-analysis identified three trials of nearly 1000 patients with established cardiovascular disease that compared moderate intensity",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy (international normalized ratio [INR] 2-3) to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/70\">",
"       70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=see_link&amp;anchor=H10160367#H10160367\">",
"       \"Chronic anticoagulation after acute coronary syndromes\", section on 'Randomized trials'",
"      </a>",
"      .) Anticoagulation was associated with a non-significant 16 percent (95% CI -11 to 37) reduction in the risk of cardiovascular death, myocardial infarction (MI), or stroke. In 13 trials (8140 patients) that compared high-intensity warfarin (INR &gt;2.8) to placebo, warfarin significantly reduced the rate of this outcome compared to placebo (2.3 versus 30.3 percent).",
"     </li>",
"     <li>",
"      The Thrombosis Prevention trial (not included in the meta-analysis) randomly assigned nearly 5000 men (without cardiovascular disease but at high risk) in a 2x2 factorial design to either to low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 mg daily) or placebo and to low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (international normalized ratio [INR] target of 1.5) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Individual trials'",
"      </a>",
"      above.) Low dose warfarin significantly reduced the rate of ischemic heart disease events compared to placebo (10.3 versus 13.3 percent). An important limitation of this study is the low INR achieved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second step is to show that anticoagulant plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is not significantly better than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    alone, given the known increase in major bleeding associated with the concomitant use of both agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the meta-analysis discussed above, three trials (over 3000 patients) compared moderate to high intensity",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (INR &gt;2) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      to warfarin alone. Combined therapy was associated with a non-significant lowering of the rate of cardiovascular death, MI, and stroke (12.5 versus 14.3 percent, respectively; odd ratio 0.86, 95% CI 0.70-1.06). The results of this analysis should be interpreted with some caution, as the achieved INR target was somewhat lower than that felt to be ideal (2.5).",
"     </li>",
"     <li>",
"      In the Thrombosis Prevention trial discussed above, combination",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      reduced the rate of ischemic heart disease (8.7 versus 10.3 percent), but the statistical significance was not reported.",
"     </li>",
"     <li>",
"      The SPORTIF trials (III and IV) evaluated the relative efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (INR 2-3) to ximelagatran in patients with atrial fibrillation and included a high percentage of patients with stable cardiovascular disease or at high risk. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H11#H11\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'INR monitoring and goal'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A post-hoc analysis compared outcomes in the 14 percent of patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      to those who did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/71\">",
"       71",
"      </a>",
"      ]. The rate of myocardial infarction with aspirin plus warfarin (0.6 percent per year) was not significantly different from that with warfarin alone (1.0 percent per year). In addition, combination therapy was associated with a significant increase in the risk of major bleeding compared to warfarin alone (3.9 versus 2.3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on limited evidence, we do not recommend routinely adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (or other antiplatelet agent) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (or other anticoagulant) to reduce the risk of ischemic cardiovascular disease events in patients with or at high risk for cardiovascular disease. There is no convincing evidence of benefit and the risk of major bleeding with combined therapy is higher. This recommendation is consistent with that made in the 2012 American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis guideline on Antithrombotic therapy for atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/12/37066/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of dual antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus a platelet P2Y12 receptor blocker) plus oral anticoagulant in patient with recent ACS or stent placement is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=see_link&amp;anchor=H11#H11\">",
"     \"Chronic anticoagulation after acute coronary syndromes\", section on 'Patients with indications for chronic anticoagulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=see_link&amp;anchor=H2#H2\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'TOAT versus other therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of our authors and reviewers are comfortable continuing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and anticoagulant therapy, especially in patients with prior MI or less than a year after stenting if there have been no significant bleeding episodes and the risk of future bleeding is low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H29#H29\">",
"     \"Therapeutic use of warfarin\", section on 'Major risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=see_link\">",
"       \"Patient information: Aspirin and cardiovascular disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611367206\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In secondary prevention,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    decreases the risk of cardiovascular disease (CVD) events in a wide range of patients with established disease. Although the randomized data are sparse, aspirin may also be of net benefit in patients with a coronary heart disease equivalent (such as patients with diabetes). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Efficacy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Primary prevention of CVD'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In all patients, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is associated with an increase in the risk of major bleeding, particularly from the gastrointestinal tract. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Bleeding risk'",
"    </a>",
"    above.) In secondary prevention, the absolute benefit is large compared to the absolute risk of major bleeding. In primary prevention, the absolute benefit is lower and must be weighted on an individual clinical basis against the absolute risk of major bleeding.",
"   </p>",
"   <p>",
"    We recommend long-term antiplatelet therapy (either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) for the secondary prevention of cardiovascular events in most patients with established CVD, including those with a history of gastrointestinal bleeding (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). In patients with a history of gastrointestinal bleeding, prevention with a proton pump inhibitor should be considered. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Efficacy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Primary prevention of CVD'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Secondary prevention of GI bleeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based on overall benefit to risk and benefit to cost considerations, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for secondary prevention (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Comparison to thienopyridines'",
"    </a>",
"    above.) Patients for whom cost is not an issue could reasonably choose clopidogrel rather than aspirin, given clopidogrel's slightly greater efficacy.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with acute coronary syndromes, in patients who have undergone revascularization procedures, or in patients after stroke is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link&amp;anchor=H3#H3\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611367213\">",
"    <span class=\"h2\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic presents an in-depth review of the evidence that can be used to formulate an approach to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the primary prevention of cardiovascular events. (See",
"    <a class=\"local\" href=\"#H438151489\">",
"     'Our approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We do not feel that we can make a broad recommendation to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the primary prevention of cardiovascular disease events. However, as the benefits of aspirin use may extend to cancer prevention, its role in primary prevention is better evaluated when the prevention of cancer is also taken into account. We recommend this broader approach, which is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=see_link\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611367220\">",
"    <span class=\"h2\">",
"     Patients taking oral anticoagulant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with either established cardiovascular disease or at high risk who have an indication for long-term oral anticoagulant therapy, we suggest not adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (or other antiplatelet therapy) (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H611366894\">",
"     'Anticoagulated patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some patients with cardiovascular disease, such as those with recent acute coronary syndrome or stent placement, require both antiplatelet and anticoagulant therapy for a defined period of time. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=see_link&amp;anchor=H11#H11\">",
"     \"Chronic anticoagulation after acute coronary syndromes\", section on 'Patients with indications for chronic anticoagulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=see_link&amp;anchor=H2#H2\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'TOAT versus other therapies'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/1\">",
"      Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/2\">",
"      Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/3\">",
"      Hennekens CH, Sechenova O, Hollar D, Serebruany VL. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions. J Cardiovasc Pharmacol Ther 2006; 11:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/4\">",
"      Hennekens CH, Schneider WR, Pokov A, et al. A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. J Cardiovasc Pharmacol Ther 2010; 15:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/5\">",
"      Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 2004; 24:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/6\">",
"      Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/7\">",
"      Grattan CE. Aspirin sensitivity and urticaria. Clin Exp Dermatol 2003; 28:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/8\">",
"      Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 2004; 292:3017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/9\">",
"      Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/10\">",
"      Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/11\">",
"      De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012; 307:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/12\">",
"      Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/13\">",
"      Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/14\">",
"      Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003; 108:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/15\">",
"      McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/16\">",
"      Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 2009; 150:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/17\">",
"      Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 2011; 9:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/18\">",
"      US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/19\">",
"      Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/20\">",
"      Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/21\">",
"      Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med 2005; 352:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/22\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/23\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 45:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/24\">",
"      Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/25\">",
"      CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/26\">",
"      Bhatt DL, Hirsch AT, Ringleb PA, et al. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000; 140:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/27\">",
"      Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001; 103:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/28\">",
"      Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/29\">",
"      Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000; 31:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/30\">",
"      Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 2000; 35:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/31\">",
"      Flather MD, Yusuf S, K&oslash;ber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/32\">",
"      Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002; 360:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/33\">",
"      Aspirin for heart patients. FDA Drug Bull 1985; 15:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/34\">",
"      Aspirin for transient ischemic attacks. FDA Drug Bull 1980; 10:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/35\">",
"      Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/36\">",
"      Hennekens CH, Buring JE, Sandercock P, et al. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/37\">",
"      Johnson ES, Lanes SF, Wentworth CE 3rd, et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999; 159:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/38\">",
"      AHA, ACC, National Heart, Lung, and Blood Institute, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/39\">",
"      Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/40\">",
"      Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/41\">",
"      Maree AO, Curtin RJ, Dooley M, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/42\">",
"      Karha J, Rajagopal V, Kottke-Marchant K, Bhatt DL. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 2006; 151:976.e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/43\">",
"      Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/44\">",
"      Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/45\">",
"      Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/46\">",
"      Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/47\">",
"      Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011; 124:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/48\">",
"      Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011; 107:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/49\">",
"      Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/50\">",
"      Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988; 318:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/51\">",
"      Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/52\">",
"      Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/53\">",
"      Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/54\">",
"      de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/55\">",
"      Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/56\">",
"      Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens 2000; 18:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/57\">",
"      Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/58\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/59\">",
"      Hennekens CH, Knatterud GL, Pfeffer MA. Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges. Diabetes Care 2004; 27:2752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/60\">",
"      Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010; 33:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/61\">",
"      Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/62\">",
"      Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/63\">",
"      Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994; 90:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/64\">",
"      Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Circulation 1995; 92:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/65\">",
"      Hennekens CH, Jonas MA, Buring JE. The benefits of aspirin in acute myocardial infarction. Still a well-kept secret in the United States. Arch Intern Med 1994; 154:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/66\">",
"      Burwen DR, Galusha DH, Lewis JM, et al. National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. Arch Intern Med 2003; 163:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/67\">",
"      Krumholz HM, Philbin DM Jr, Wang Y, et al. Trends in the quality of care for Medicare beneficiaries admitted to the hospital with unstable angina. J Am Coll Cardiol 1998; 31:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/68\">",
"      Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000; 101:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/69\">",
"      Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001; 24:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/70\">",
"      Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003; 41:62S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/71\">",
"      Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006; 152:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/12/37066/abstract/72\">",
"      You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e531S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1513 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37066=[""].join("\n");
var outline_f36_12_37066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASPIRIN NONRESPONSE AND RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASPIRIN SENSITIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BLEEDING RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dosing and bleeding risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Primary prevention of aspirin induced GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Secondary prevention of GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NONASPIRIN NSAIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SECONDARY PREVENTION OF CVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Use in heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Comparison to thienopyridines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cessation of aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Concomitant use of ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dosing and cardiovascular benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Aspirin formulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PRIMARY PREVENTION OF CVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Individual trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Estimating the benefit to risk ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Impact of age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Impact of gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Impact of diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H80547560\">",
"      Possible benefit for the prevention of cancer related events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H438151489\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      UNDERUTILIZATION OF ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H611366894\">",
"      ANTICOAGULATED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H611367206\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H611367213\">",
"      Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H611367220\">",
"      Patients taking oral anticoagulant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1513\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1513|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/34/43564\" title=\"table 1\">",
"      Effect of antiplatelet therapy on vascular events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/17/32027\" title=\"table 2A\">",
"      Aspirin 10 yr risk levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/33/44573\" title=\"table 2B\">",
"      Benefits and harms of aspirin when used for 10 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/62/2030\" title=\"table 2C\">",
"      MIs prevented and harms of aspirin for 10 years",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?43/28/44482?source=related_link\" title=\"calculator 1\">",
"      Calculator: Framingham 10 year risk of general cardiovascular disease in men (2008 paper)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/63/10226?source=related_link\" title=\"calculator 2\">",
"      Calculator: Framingham 10 year risk of general cardiovascular disease in women (2008 paper)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=related_link\">",
"      Aspirin in the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=related_link\">",
"      Chronic anticoagulation after acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26006?source=related_link\">",
"      Diagnostic challenge and desensitization protocols for NSAID reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42039?source=related_link\">",
"      Drugs that should be avoided or used with caution in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/58/12197?source=related_link\">",
"      NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=related_link\">",
"      Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=related_link\">",
"      Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4167?source=related_link\">",
"      The role of platelets in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_12_37067="Supportive care variceal bleed";
var content_f36_12_37067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Supportive care of patients with active variceal hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hemodynamic resuscitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Packed red cell transfusion to keep hemoglobin at about 9 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crystalloids to keep urine volume &gt;50 mL/h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Correct coagulopathy and thrombocytopenia as indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid volume overload",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary resuscitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor airway integrity and oxygen saturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protect airway if mental status obtunded or if active hemetemesis present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norfloxacin for high-risk subjects with ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor closely for signs of sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid transfusion mismatch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid aminoglycosides and other nephrotoxic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maintain euvolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor for alcohol withdrawal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiamine replacement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor for hypokalemia, hypophosphatemia, and acid-base balance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor for acid-base balance and correct as necessary",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37067=[""].join("\n");
var outline_f36_12_37067=null;
var title_f36_12_37068="Calcium content of supplements";
var content_f36_12_37068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Elemental calcium content per pill of different calcium supplements",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elemental Ca/tablet",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ca compound",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vitamin D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caltrate + D",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        800 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        OsCal 500",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        OsCal 500 + D",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        200 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oscal 500 + Extra D",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        400 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oscal Ultra",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        500 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tums",
"       </td>",
"       <td>",
"        200 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tums EX",
"       </td>",
"       <td>",
"        300 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tums Ultra",
"       </td>",
"       <td>",
"        400 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citracal Ultradense Petites",
"       </td>",
"       <td>",
"        200 mg",
"       </td>",
"       <td>",
"        Citrate",
"       </td>",
"       <td>",
"        250 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citracal caplets + D",
"       </td>",
"       <td>",
"        315 mg",
"       </td>",
"       <td>",
"        Citrate",
"       </td>",
"       <td>",
"        250 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citracal 250 + D",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"       <td>",
"        Citrate",
"       </td>",
"       <td>",
"        200 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citracal + D Slow Release",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"       <td>",
"        Citrate",
"       </td>",
"       <td>",
"        500 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caltrate 600 + soy",
"       </td>",
"       <td>",
"        600 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        200 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cal-100 with vitamin D",
"       </td>",
"       <td>",
"        1000 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        400 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citracal gummy",
"       </td>",
"       <td>",
"        250 mg",
"       </td>",
"       <td>",
"        Tricalcium phosphate",
"       </td>",
"       <td>",
"        250 Units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viactiv plus D + K",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Carbonate",
"       </td>",
"       <td>",
"        500 Units",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Units: International Units.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37068=[""].join("\n");
var outline_f36_12_37068=null;
var title_f36_12_37069="Components cardiovascular risk";
var content_f36_12_37069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81993%7ENEPH%2F72683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81993%7ENEPH%2F72683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Components of cardiovascular risk factors in patients with hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Major risk factors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cigarette smoking",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Obesity (BMI &ge;30 kg/m2)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Physical inactivity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dyslipidemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetes mellitus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Microalbuminuria or estimated GFR &lt;60 mL/min",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Age &gt;55 years for men, &gt;65 years in women",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Family history of premature coronary disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Men - &lt;55 years",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Women - &lt;65 years",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Target organ damage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Left ventricular hypertrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Angina or prior myocardial infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Prior coronary revascularization",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Heart failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stroke or transient ischemic attack",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic kidney disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peripheral arterial disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retinopathy",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. The JNC 7 report. JAMA 2003; 289:2560.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification and management of blood pressure for adults aged 18 years or older",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        BP classification",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Systolic BP mmHg*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Diastolic BP mmHg*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Management*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"1\" rowspan=\"2\">",
"        Lifestyle modification",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Initial drug therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Without compelling indication",
"       </td>",
"       <td class=\"subtitle3\">",
"        With compelling indications&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        &lt;120",
"       </td>",
"       <td>",
"        and",
"       </td>",
"       <td>",
"        &lt;80",
"       </td>",
"       <td>",
"        Encourage",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prehypertension",
"       </td>",
"       <td>",
"        120-139",
"       </td>",
"       <td>",
"        or",
"       </td>",
"       <td>",
"        80-89",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No antihypertensive drug indicated",
"       </td>",
"       <td>",
"        Drug(s) for the compelling indications&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 1 hypertension",
"       </td>",
"       <td>",
"        140-159",
"       </td>",
"       <td>",
"        or",
"       </td>",
"       <td>",
"        90-99",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Thiazide-type diuretics for most; may consider ACE inhibitor, ARB, beta blocker, CCB, or combination",
"       </td>",
"       <td>",
"        Drug(s) for the compelling indications; other anti-hypertensive drugs (diuretics, ACE inhibitor, ARB, beta blocker, CCB) as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 2 hypertension",
"       </td>",
"       <td>",
"        &ge;160",
"       </td>",
"       <td>",
"        or",
"       </td>",
"       <td>",
"        &ge;100",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        2-drug combination for most (usually thiazide-type diuretic and ACE inhibitor or ARB or beta blocker or CCB)&loz;",
"       </td>",
"       <td>",
"        Drug(s) for the compelling indications; other antihypertensive drugs (diuretics, ACE inhibitor, ARB, beta blocker, CCB) as needed",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blocker; BP: blood pressure; CCB: calcium channel blocker.",
"     <br>",
"      * Treatment determined by highest BP category.",
"      <br>",
"       &Delta; Treat patients with chronic kidney disease or diabetes to BP goal of less than 130/80 mmHg. Other compelling indications include disorders such as heart failure, post-myocardial infarction, and atrial fibrillation in which particular antihypertensive drugs are warranted independent of BP.",
"       <br>",
"        &loz; Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289:2560.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37069=[""].join("\n");
var outline_f36_12_37069=null;
var title_f36_12_37070="Antidepressants in older adults and medically ill";
var content_f36_12_37070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug properties and doses of antidepressants in older adults and medically ill",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Starting dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggested dose range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Precautions*",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;Potential advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        &nbsp;",
"        <strong>",
"         Selective serotonin reuptake inhibitors (SSRIs)",
"         <sup>",
"          &bull;",
"         </sup>",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Escitalopram",
"       </td>",
"       <td>",
"        5 mg every morning or every evening",
"       </td>",
"       <td>",
"        5 to 20 mg daily",
"       </td>",
"       <td>",
"        Mild discontinuation symptoms may occur absent tapering.",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Applies to escitalopram and citalopram:",
"        </p>",
"        <p>",
"         Generally well tolerated.&nbsp; Non-sedating, low risk of sleep disturbance, comparatively few significant drug interactions.",
"        </p>",
"        Good choice for initial&nbsp;treatment of depression in most older adults.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citalopram",
"       </td>",
"       <td>",
"        10 mg every morning or every evening",
"       </td>",
"       <td>",
"        10 to&nbsp;20 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"        daily",
"       </td>",
"       <td>",
"        <p>",
"         Dose related risk of QT&nbsp;prolongation.",
"         <sup>",
"          &bull;&Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Mild discontinuation symptoms may occur absent tapering.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sertraline",
"       </td>",
"       <td>",
"        12.5 to 25 mg every morning",
"       </td>",
"       <td>",
"        25 to 200 mg daily",
"       </td>",
"       <td>",
"        More frequent gastrointestinal symptoms including diarrhea. Variable oral bioavailability.&nbsp;Oral solution contains alcohol. Discontinuation symptoms may occur absent tapering.",
"       </td>",
"       <td>",
"        <p>",
"         Non-sedating, low risk of insomnia,&nbsp;lacks significant cardiovascular effects.",
"        </p>",
"        <p>",
"         Good choice for initial&nbsp;treatment of depression in most older adults.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoxetine",
"       </td>",
"       <td>",
"        5 to 10 mg every morning",
"       </td>",
"       <td>",
"        5 to 60 mg daily",
"       </td>",
"       <td>",
"        <p>",
"         Activating.",
"        </p>",
"        <p>",
"         Significant drug interactions.",
"        </p>",
"        <p>",
"         Prolonged half-life and active metabolites require weeks to reach steady-state, prolonging time needed to evaluate effect of dose adjustment and complicating wash-out and withdrawal.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Activating effect&nbsp;may be&nbsp;useful for treatment of&nbsp;depressed patients with low energy&nbsp;or hypersomnia. Tapering&nbsp;upon discontinuation&nbsp;is not needed due to long half-life.&nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paroxetine",
"       </td>",
"       <td>",
"        10 mg every evening",
"       </td>",
"       <td>",
"        10 to 40 mg every evening",
"       </td>",
"       <td>",
"        <p>",
"         Weakly anticholinergic. May cause constipation, dry mouth or drowsiness.",
"        </p>",
"        <p>",
"         Associated with more severe discontinuation symptoms in absence of tapering.",
"        </p>",
"       </td>",
"       <td>",
"        Useful for patients with insomnia.&nbsp;Moderate half-life with no active metabolites.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluvoxamine",
"       </td>",
"       <td>",
"        25 mg every evening",
"       </td>",
"       <td>",
"        25 to 200 mg every evening",
"       </td>",
"       <td>",
"        Significant drug interactions. Short half-life associated with discontinuation symptoms in absence of tapering.",
"       </td>",
"       <td>",
"        May be useful for patients with insomnia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         Serotonin-norepinephrine reuptake inhibitors (SNRIs)",
"         <sup>",
"          &loz;",
"         </sup>",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venlafaxine (extended release)",
"       </td>",
"       <td>",
"        <p>",
"         37.5 mg once daily",
"        </p>",
"       </td>",
"       <td>",
"        75 to 225 mg once daily",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Applies to venlafaxine and desvenlafaxine:",
"        </p>",
"        <p>",
"         Activating.",
"        </p>",
"        <p>",
"         May cause dose-dependent increases in blood pressure (primarily diastolic) and heart rate. Monitor blood pressure regularly.",
"        </p>",
"        <p>",
"         Gastrointestinal symptoms (eg, nausea) may be more prominent with immediate release venlafaxine.",
"        </p>",
"        <p>",
"         Associated with discontinuation symptoms absent tapering. Taper desvenlafaxine by increasing interval between doses.",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Applies to venlafaxine and desvenlafaxine: activating effect&nbsp;may be&nbsp;useful for treatment of&nbsp;melancholic depressed patients with low energy or hypersomnia.",
"        </p>",
"        <p>",
"         Useful for patients with co-morbid painful conditions such as diabetic neuropathy.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venlafaxine (immediate release)",
"       </td>",
"       <td>",
"        <p>",
"         18.75 to 37.5 mg every morning or twice daily",
"        </p>",
"       </td>",
"       <td>",
"        75 to 150 mg twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desvenlafaxine",
"       </td>",
"       <td>",
"        <p>",
"         50 mg every morning",
"        </p>",
"        <p>",
"         CrCl &lt; 30 mL/min: 50 mg every other day",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         50 mg&nbsp;every morning",
"        </p>",
"        <p>",
"         CrCl &lt; 30 mL/min: 50 mg every other day",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duloxetine",
"       </td>",
"       <td>",
"        10 to 20 mg daily",
"       </td>",
"       <td>",
"        20 to 60 mg once daily",
"       </td>",
"       <td>",
"        Significant drug interactions.",
"       </td>",
"       <td>",
"        <p>",
"         Mildy sedating. Low risk of insomnia.",
"        </p>",
"        <p>",
"         Useful for patients with comorbid painful conditions such as diabetic neuropathy or chronic pain.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         Atypical antidepressants",
"         <sup>",
"          &loz;",
"         </sup>",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mirtazapine",
"       </td>",
"       <td>",
"        7.5 mg every evening",
"       </td>",
"       <td>",
"        15 to 60 mg every evening",
"       </td>",
"       <td>",
"        <p>",
"         Prolonged half-life and active metabolites.&nbsp; Risk of accumulation with renal and/or hepatic insufficiency.&nbsp; Dose reductions necessary.",
"        </p>",
"        <p>",
"         Drowsiness, weight gain. Rare reports of agranulocytosis.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Sedating. Low risk of sexual dysfunction.&nbsp;",
"        </p>",
"        <p>",
"         Appetite&nbsp;stimulant and anti-nausea&nbsp;effects can be noted within days.",
"        </p>",
"        <p>",
"         Useful for patients with insomnia or&nbsp;who may benefit from weight gain.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bupropion sustained release",
"       </td>",
"       <td>",
"        75 mg in morning initially then twice daily",
"       </td>",
"       <td>",
"        150 mg in morning and mid-afternoon (twice daily)",
"       </td>",
"       <td>",
"        Avoid in seizure disorders and depressed patients with agitation.&nbsp; Dose-dependent increase in diastolic blood pressure. May worsen insomnia.&nbsp;",
"       </td>",
"       <td>",
"        Stimulant effect&nbsp;may be&nbsp;useful for treatment of&nbsp;depressed patients with low energy and apathy. Low risk of cognitive toxicity. Dopaminergic&nbsp;action may be&nbsp;advantageous for depressed&nbsp;patients with Parkinson disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vilazodone",
"       </td>",
"       <td>",
"        10 mg once daily with food&nbsp;for 7 days or more",
"       </td>",
"       <td>",
"        20 to 40&nbsp;mg once daily with&nbsp;food&nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Take with food to assure bioavailability.",
"        </p>",
"        <p>",
"         Diarrhea, nausea, vomiting, dizziness, insomnia.",
"        </p>",
"        <p>",
"         Significant drug interactions via CYP 3A4&nbsp;require dose adjustment.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Low incidence of weight gain or sexual dysfunction.",
"        </p>",
"        <p>",
"         Role in therapy for treatment of depressed&nbsp;older adults or adults with comorbid illness is not yet defined.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trazodone",
"       </td>",
"       <td>",
"        12.5 to 25 mg taken&nbsp;30 to 60 minutes&nbsp;before bedtime for hypnotic effects",
"       </td>",
"       <td>",
"        25&nbsp;to 100 mg taken 30 to 60 minutes before bedtime for hypnotic effects; antidepressant effects require higher doses.",
"       </td>",
"       <td>",
"        Sedation, orthostatic hypotension, nausea. Residual daytime sedation and cognitive impairment.&nbsp; Reports of hyponatremia.",
"       </td>",
"       <td>",
"        Used in low doses as adjunct to SSRI for treatment of insomnia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         Tricyclic antidepressants (TCAs)",
"         <sup>",
"          &sect;",
"         </sup>",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nortriptyline",
"       </td>",
"       <td>",
"        10 mg every evening",
"       </td>",
"       <td>",
"        10 to 100 mg every evening or in two&nbsp;divided doses",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Applies to nortriptyline and desipramine:",
"        </p>",
"        <p>",
"         May be poorly tolerated by medically ill and older adults due to anticholinergic effects which include dry mouth, constipation, urinary retention or altered vision (eg, avoid in prostatic disease or narrow angle glaucoma).",
"        </p>",
"        <p>",
"         May be fatal in overdose.",
"        </p>",
"        <p>",
"         Potentially cardiotoxic, can cause arrhythmia or orthostatic hypotension.",
"        </p>",
"        <p>",
"         Significant drug interactions.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Applies to nortriptyline:",
"        </p>",
"        <p>",
"         Established therapeutic serum concentration 50 to 150 ng/mL.",
"        </p>",
"        <p>",
"         Mildly sedating. Taken at bed time for depressed patients with insomnia.&nbsp;",
"        </p>",
"        <p>",
"         May be useful for melancholic, anxious depressed patients who have not responded to first and second line antidepressants.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desipramine",
"       </td>",
"       <td>",
"        10 mg every morning",
"       </td>",
"       <td>",
"        25 to&nbsp;150 mg every&nbsp;morning or in two divided doses",
"       </td>",
"       <td>",
"        <p>",
"         Applies to desipramine:",
"        </p>",
"        <p>",
"         Established therapeutic serum concentration 125 to 300 ng/mL.&nbsp;&nbsp;",
"        </p>",
"        <p>",
"         Mild stimulant effects may be&nbsp;useful&nbsp;for depressed patients with low energy and hypersomnia who have not responded to first and second line antidepressants.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Specific interactions of&nbsp;antidepressants&nbsp;with other medications may be determined using the Lexi-Interact&trade; drug interactions program&nbsp;included&nbsp;with UpToDate.",
"     <br>",
"      &bull; For additional information refer to topic on unipolar depression in adults and SSRIs.",
"      <br>",
"       &Delta; Maximum recommended daily&nbsp;dose of citalopram is 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking interacting medications that can increase citalopram levels.",
"       <br>",
"        &loz; For additional information refer to topic on SNRIs and other antidepressants for treating depressed adults.",
"        <br>",
"         &sect; For additional information&nbsp;refer to topic on tricyclic and tetracyclic antidepressants for treating depressed adults.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37070=[""].join("\n");
var outline_f36_12_37070=null;
var title_f36_12_37071="Athletes foot PI";
var content_f36_12_37071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute tinea pedis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows tinea pedis (athlete's foot) on the toe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_12_37071=[""].join("\n");
var outline_f36_12_37071=null;
